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ABSTRACT 
HUMAN MUTATION/SUBSTITUTION RATE: VARIABILITY, MODELING AND APPLICATIONS 
Varun Aggarwala  
Benjamin F. Voight 
 
Mutation generates genetic variation, and in turn selection purges deleterious variants from the 
population. Understanding both is critical for discovering causal genes and variants behind 
diseases or making inferences about evolutionary processes. Human mutation rate varies 
significantly across the genome although most studies have only considered the immediate 
flanking nucleotides around the polymorphic site to model and study patterns of variability. The 
impact of larger sequence context has not been fully clarified, even though it substantially 
influences rates of mutation. In the first part of this thesis, I develop a novel statistical framework 
and using data from the 1000 Genomes project, demonstrate that a larger heptanucleotide 
sequence context explains >81% variability in substitution probabilities, discovering novel 
mutation promoting motifs at ApT dinucleotides, CAAT, and TACG sequences. My approach also 
reveals previously undocumented variability in C-to-T substitutions at CpG sites, not immediately 
explained by differential methylation intensity. Building on this framework, I model the selective 
forces acting on the coding genome and develop statistical scores that measures the intolerance 
at the gene or amino-acid level for functional variants. I demonstrate clinical utility of such 
intolerance scores in identifying genes associated with multiple human diseases including Autism. 
Next, I apply these lessons of mutation rate variability to develop an algorithm to detect sub-genic 
enrichment of de novo germline mutations in RB1 gene of bilateral Retinoblastoma (RB) 
probands to further elucidate disease biology. I demonstrate that previously noted ‘hotspots’ of 
nonsense mutations in RB1 are compatible with the elevated mutation rates expected at CpG 
sites, refuting a specific mechanism in RB pathogenesis. I also find enrichment of splice-site 
donor mutations of exon 6 and 12 but depletion at exon 5, indicative of previously unappreciated 
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heterogeneity in penetrance within this class of substitution. Finally, I generate more accurate and 
informative estimates of de novo germline mutation rate in humans, and develop a toolkit to 
simulate, distribute and interpret mutations in human diseases. Overall, my research uncovers 
novel variability in human mutation rate and provides a systematic framework for analyzing 
mutational data, which can be used from causal gene discovery to elucidating specific disease 
mechanisms. 
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CHAPTER 1: Introduction 
Human mutation rate 
Mutation is the most important force that has shaped our genomes since we evolved from single 
cell species [1]. It generates genetic variation on which evolution acts [2], causes variation 
between individuals of same [3] and different species [4], results in cell to cell heterogeneity [5] 
and is responsible for genetic disorders; inherited [6] or somatic [7] like cancer. Hence, 
understanding how mutations originate across the genome is fundamental to our understanding 
of life. Previous work over the last century, has successfully discovered and described the 
process of mutation [3, 8] in single celled organisms to complex eukaryotic species like Homo 
sapiens. Here, I define mutation rate as the measure of the rate at which mutations occur in the 
human genome over time. An accurate estimate of the human mutation rate can shed light on the 
process of mutagenesis and is essential for all aforementioned quantitative applications which 
model and utilize the properties of mutation.  
There are three major approaches to study the human mutation rate. The earliest is the 
phylogenetic approach [3, 8–10], which measures fixed substitutions at neutral sites between 
species to find an estimate of mutation rate. Traditionally, fixed substitutions at putatively neutral 
evolving pseudogenes were measured to get an estimate of mutation rate. This approach also 
requires the divergence time between species, which is estimated from fossil dating [11] to get an 
estimate of mutation rate. This approach has been quite informative and provided the initial clues 
about the general properties of mutation and its variation, which helped improved our 
understanding of the process of mutagenesis [3, 8]. However several issues remain with this 
approach as it makes several assumptions about the accuracy of species divergence time, and 
putatively neutral evolving nature of pseudogenes [12]. Moreover, issues of multiple substitutions 
at a site and small number of substitutions at pseudogenes also add uncertainty to the mutation 
rate estimates. Next, with the advent of next generation sequencing the community has tried to 
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infer the properties of mutation  from large scale population sequencing datasets [13, 14]. 
Assuming that intergenic noncoding regions are neutrally evolving and hence effects of selection 
are minimized, they can be studied to understand the properties of mutation rate [11, 15]. This 
approach is informative, however we only learn about general properties of mutation and how it 
has shaped the genetic variation spectrum in putative neutral regions, but we do not get actual 
estimates of mutation rate. Another informative approach involves resequencing of family trios 
(i.e., parents and the offspring) to identify de novo mutations, from which a rate per generation 
can be estimated [16–18]. This approach is unbiased, but suffers from issues of extremely small 
sample sizes as only ~70 de novo mutations are observed genome-wide in a family. Even with 
larger family sizes, resulting in thousands of mutations, we are limited in our power to completely 
understand the properties of mutation and accurately infer the mutation rate. Moreover, due to 
numerous filters and quality control measures, many real mutations are omitted from the final set 
of high quality de novo mutations. In future, with large sample sizes and higher fold coverage of 
sequencing studies these issues can be resolved, but in current form the direct sequencing 
approach is severely underpowered. Hence, despite statistical and technological advances, many 
gaps in knowledge about the process of mutagenesis, related to mechanism and discovery of 
novel determinants of mutation still remain. 
Mutations can arise due to both endogenous or exogenous sources. Endogenous sources might 
be due to errors introduced during replication [19, 20] or due to spontaneous changes [21, 22]. 
Well characterized sources of exogenous factors resulting in mutation are radiation and chemical 
agents [23]. While most errors are corrected by the DNA repair machinery [24], if left uncorrected 
it results in a mutation. Since replication introduced errors result in mutation, this also explains the 
high paternal effect on human mutation rate due to the increased number of cell divisions in 
spermatogenesis [25]. Most replication errors arise from incorrect base incorporation resulting in 
point mutations or slippage of polymerase which results in short indels [26]. It is important to note 
that DNA repair is more effective in regions where DNA strands can be readily separated [27]. 
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Since, A-T base pairs have two hydrogen bonds, in contrast to the three stronger hydrogen bonds 
at G-C base pairs, it is more difficult to separate DNA in GC rich region, resulting in a higher rate 
of mutation here. An exquisite example of spontaneous change resulting in a higher mutation rate 
is the deamination of methylated cytosine at CpG sequence context [28, 29]. Multiple studies 
have characterized the higher mutation rate here (~15 fold higher than the genome-wide 
average) and this context is almost exclusively modeled in all studies of mutation rate and its 
variation [30–33]. Well established exogenous factors that induce mutation includes UV light 
exposure which can result in C-to-T transition at di-pyrimidine sequences [34] or G-to-T 
transversions caused by Benzo(a)pyrene [35]. Characterization and understanding of mutational 
signatures and associated mechanism has direct relevance in multiple human diseases including 
cancer. The advent of next generation sequencing has revolutionized the field of mutation 
research, as novel mutational signatures [36] are observed from direct sequencing of germline 
and somatic tissues (mostly in different cancer). However, many open questions about the 
process of mutagenesis still remain and systematic approaches are needed to discover novel 
mutational signatures from large scale sequencing datasets, which can then elucidate the 
associated mechanisms and factors causing mutation.  
Since mutations arise due to a host of different exogenous and endogenous factors, which result 
in different mutational signatures, it is natural to expect variation in the genome-wide rate of 
mutation. Previous studies over the last few decades have reported extensive variation in the 
mutation rate across the genome [3, 8], much more than one would have expected from known 
sources which confer variability. Mutation rate has been shown to vary at a broad scale of 
chromosome to individual base pairs. Over broad scales, replication timing has been shown to 
influence the rate of mutation. In particular, the late replicating regions [19, 20] have been shown 
to have a higher mutation rate and associated SNP density, potentially due to scarcity of free 
nucleotides during replication. Processes like transcription coupled repair, has also been shown 
to affect the rate of mutation [37]. Since this process is more prominent over actively transcribed 
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regions, more mutations are observed in the non-transcribed strand and this asymmetry is more 
pronounced for highly expressed ubiquitous genes [38]. At fine scale, local sequence context has 
been shown to strongly influence the rate of mutation, much more than broad scale effects. First, 
we observe a two-fold higher rate of transitions than transversions, which can be explained by 
relative ease of purine to purine or pyrimidine to pyrimidine DNA mispairing during replication, 
resulting in a transition mutation [39]. Second, adjacent sequence context explains significant 
variation in the rate of mutation [30]. For example, it captures properties of spontaneous 
deamination of methylated cytosine resulting in a thymine mutation at CpG motif. Virtually all 
studies use trinucleotide sequence context (which considers one nucleotide at either 5’ and 3’ 
end) around a polymorphic site to summarize and model the genome-wide variability in mutation 
rate from applications ranging from basic science understanding of mutagenesis [32, 33], in 
different cancers, and in developing clinical applications [31]. However, open questions still 
remain. Does the trinucleotide sequence context capture all or most variation in mutation rate? If 
not, what size window of sequence context best explains patterns of genetic variation we observe 
in human populations? With improved models that explain observed data to a greater extent than 
previous possible, (i) are there features beyond CpG sites that further enumerate the processes 
and potential mechanism that cause mutation, and (ii) how can we employ this improved 
understanding to power studies of human disease? In this dissertation, I systematically address 
these questions related to mutation rate variability. 
Purifying selection 
Purifying or negative selection is the act of purging of deleterious variants from the population 
[40]. Since new mutations in functional regions like protein coding genes are mostly deleterious 
and reduce organismal fitness [41, 42], purifying selection by removing these mutations maintains 
the genomic integrity. Forces of evolution and drift over the course of time have optimized the 
genome of most species and hence new deleterious mutations are kept from increasing in 
number and taking over the fixed variants. It is also important to note that some new mutations 
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can also increase fitness, hence they are selected for in the population and reach fixation [43]; 
this phenomenon is called positive selection. Moreover, in cases where having heterozygous 
alleles is beneficial, evolution acts to actively maintain multiple alleles in the population [44]; this 
phenomenon is called balancing selection. While both positive and balancing selection has been 
observed in the genome, purifying selection remains the most common and prevalent of all [45].  
Purifying selection is strongest on variants in the protein coding genes or regions with regulatory 
potential, because they have a higher likelihood to adversely affect organismal fitness [46]. 
Purging of deleterious variants can also remove linked variation [40], resulting in a reduction of 
variation surrounding the locus under selection; this phenomenon is called background selection.  
The signal of purifying selection is used to identify functionally important and highly conserved 
regions from comparative genomic approaches, because it manifests as lack of variation at a 
locus. Improvement our understanding of the frequency, occurrence, and strength of negative 
selection can inform the genetics of both human disorders and predict population frequencies of 
causal disease alleles which can further aid in screening and surveillance [47]. We expect strong 
purifying selection on genes associated with monogenic disorders because highly penetrant 
alleles in these genes can severely reduce organismal fitness [47, 48]. In contrast, weaker 
purifying selection may act on alleles in many genes which individually confer some risk for a 
complex disease [49]. Overall, genes evolving under weak purifying selection or constraint are 
thought to be less important or have more redundancy than those evolving under strong purifying 
selection [50]. 
Existing approaches to discover causal variants and genes for different disorders often utilize 
some form of conservation or purifying selection in their methodology [51]. The community has 
successfully identified numerous causal genes for both monogenic and complex diseases by 
identifying regions undergoing strong purifying selection and then prioritizing those regions for 
follow up [47, 50, 52, 53]. Such approaches will vastly benefit from more accurate estimates of 
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purifying selection and its strength of action on the genome. Approaches for finding purifying 
selection have largely focused on comparative genomic approaches to find evolutionary 
conserved regions [54, 55] or by considering the site frequency spectrum and measuring the 
enrichment of low frequency and reduction in medium and high frequency variants undergoing 
strong selection [56]. While these approaches have been informative, open questions and 
challenges still remain. Have we identified the force of selection and constraint on all genes and 
sub-genic locus? Can we further improve the estimates of selection and rank regions by strength 
of selection on them?  
It is important to note that human genetic variation is shaped both due to forces of mutation and 
selection [57]. With an accurate model for the background rate of mutation, it should be possible 
to characterize the effects of background selection, based on the difference between the genetic 
variation compared to the model expectation at a locus (or gene). While this does not result in a 
direct estimate of purifying selection, different loci can be compared to each other and can be 
ranked by the deviation from this expectation as a proxy for the strength of negative selection at 
the gene. In this dissertation, I model the rate of mutation across the genome and, using those 
rates, obtain an estimate of purifying selection at each translated gene in the genome, which can 
then be used in several clinical applications. 
Landscape of genetic diseases 
Deleterious mutations in protein coding genes can cause several diseases [58]. These 
deleterious mutations can either be inherited, occur de novo or as somatic changes in the 
affected proband [59]. Adding an extra layer of complexity, genetic diseases have a spectrum of 
genetic architecture, ranging from single gene (monogenic) to multiple genes in combination with 
environmental factors (complex, multifactorial or polygenic). Here, I will review two diseases, one 
single gene and one complex (multi-gene).  
Retinoblastoma, a monogenic disease 
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Retinoblastoma (RB) is a cancer of the developing retina caused due to bi-allelic inactivation of 
the tumor suppressor gene, RB1 [60]. The incidence rate of RB in human population is 
approximately 1 in 20,000 live births [61]. It occurs in non-hereditary form in ~60% of cases, 
characterized by tumor in one eye and is also known as unilateral Retinoblastoma [62]. The non-
hereditary form of RB occurs later in childhood and is not associated with a higher risk of other 
cancers. In contrast, the hereditary form of RB, with a frequent clinical manifestation of tumors in 
both the eyes, is characterized by germline mutations - either inherited or de novo - in the RB1 
gene [63]. This form of RB is also called bilateral Retinoblastoma and it occurs early in childhood, 
and is also characterized by higher risk of other cancers. 
Knudson [64] proposed a two-hit disease theory for Retinoblastoma. According to this theory, RB 
is caused by mutations in both copies of the tumor suppressor RB1 gene. If one mutation in the 
RB1 gene is present in germline, then only one another somatic mutation is needed to develop 
RB. This explains why bilateral RB, with a germline mutation already present in RB1 gene, occurs 
early in childhood and is characterized with cancer in both the eyes. However, unilateral 
Retinoblastoma with no germline mutations require two somatic mutations which cause 
inactivation of the RB1 gene resulting in delayed onset with tumor in one eye. 
Clinical sequencing of the RB1 gene, management and counseling of RB is now a routine 
practice for patients and their families [65, 66]. Because individuals with bilateral form of 
Retinoblastoma can transmit the germline mutations to their offspring, it is necessary to 
distinguish this form of RB from unilateral cases. Moreover, individuals with bilateral RB are also 
more likely to develop second malignancies, so the clinical management of these individuals 
allow for appropriate treatment and long-term surveillance for other cancer types. 
Multiple groups over the last few decades have sequenced the RB1 gene in patients with both 
forms of Retinoblastoma and have hypothesized several disease mechanisms from large 
mutation datasets [67, 68]. Several pathogenic mutations and their role have been identified [69–
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72], such as an abundance of nonsense mutations in RB patients which result in loss of function 
of the RB1 protein, or patterns of penetrance and pathogenicity in missense mutations. However, 
several open questions about more pathogenic sub-genic locus in RB1 gene which can further 
elucidate disease mechanism still remain. In this dissertation, I will use concepts from mutation 
rate variation to analyze RB mutation datasets along with large-scale surveys of population level 
variation in the coding genome [73] to test hypotheses about pathogenicity with sub-sequences of 
RB1. 
Autism, a complex disease 
Autism is neurodevelopmental disorder characterized by impairment in social interactions and 
repetitive behaviors [74]. It occurs in roughly 1% of the population, although the rate of incidence 
has been increasing in recent times [75], mostly due to increased awareness and broadening of 
diagnostic criteria. Males are roughly 4 times more likely than females to have a diagnosis of 
Autism [76]. Autism is a spectrum disorder and patients show vast phenotypic heterogeneity in 
cognitive and language abilities [77]. Moreover, Autism spectrum disorder rarely occurs in 
isolation, and often coexists with other neuropsychiatric and medical conditions like epilepsy, 
intellectual disability, anxiety, attention-deficit/hyperactive disorder and gastrointestinal problems 
[78]. Autism spectrum disorders (ASD) are generally diagnosed in early childhood before the age 
of 3 but symptoms often manifest late into adulthood.  
ASD has a strong genetic component as identified from twin studies and recurrence risk in 
families [79]. Twin studies for ASD have demonstrated a concordance rate of ~90% in 
monozygotic and ~up to 20% in dizygotic twins [80, 81]. Epigenetic and environmental factors are 
also thought to be influence susceptibility to ASD, since concordance rate in monozygotic twins 
does not reach 100%. Early genetic causes of ASD were identified in monogenic diseases such 
as fragile X syndrome, neurofibromatosis and Rett syndrome [82, 83] and from large scale 
chromosomal duplication or deletion [84]. However, with improved genotyping and sequencing 
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technologies, pathogenic mutations were identified in several candidate genes and they together 
highlighted the role of synaptic dysfunction in ASD susceptibility [85]. Multiple genotyping studies 
have also demonstrated the role of small and large copy number variants, both inherited and de 
novo in individuals with ASD [86–88]. Recent sequencing studies have also identified a higher 
burden or rare and de novo variants in intolerant genes (under a strong selective constraint [31]), 
specifically encoding proteins for synaptic formation, transcriptional regulation and chromatin 
remodeling pathways [52, 89, 90]. However, many open questions related to discovery of causal 
genes for Autism which can explain a higher percentage of heritability [91], and associated 
mechanism still remain. 
In this dissertation, I will use concepts from mutation rate variation to analyze a larger de novo 
sequencing dataset for Autism probands, and test for role of several causal genes in ASD 
pathogenesis. 
Sequencing approaches 
Population level sequencing 
This approach involves sequencing of unrelated individuals in a population to find the 
polymorphic events present in the genome [13, 92]. In this dissertation, I mostly focused on single 
nucleotide polymorphisms (SNPs), though population level sequencing also detects indels and 
copy number variations. An important goal of population level sequencing involves finding the 
frequency of different polymorphisms, which can help understand the role of mutation, selection, 
drift and other evolutionary forces in shaping the human genome [15, 57, 93]. Various studies 
also perform population sequencing in both affected cases and controls, to understand the role of 
common and low frequency variants in disease pathogenesis [94, 95]. Studies which focus on 
understanding population genetics parameters, generally sequence the entire genome of the 
individuals [13], while disease based studies have mostly focused on exome sequencing [96] or 
targeted sequencing of genomic regions [97].  
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The choice of tissue for most population level sequencing studies is blood, because of ease of 
collection and quality of DNA. However, because of issues of mosaicism [98], many studies 
sequence multiple tissues for accurate detection of polymorphisms present in the germline. Since 
population level sequencing entails sequencing of unrelated individuals to find polymorphisms 
and the associated frequency of alleles in the population (i.e., the site frequency spectrum), 
special emphasis is given on finding relatedness and detecting ancestry of individuals in a 
population [99].  
Rapid sequencing of multiple individuals in a population has been made possible due to advent of 
next generation sequencing technology [100], and advances in computing infrastructure for 
storage of large datasets and increased computing power for sequence alignment and variant 
calling. Moreover, due to population level sequencing of unrelated individuals in a population, 
accurate variant calling from low pass sequencing (less coverage) is possible. However, some 
regions of the genome are hard to sequence [101] and hence variant calling is still a challenging 
task. Nonetheless, with high quality sequencing datasets and more coverage, the community is 
trying to successfully identify more polymorphisms and study them in different contexts.  
In this dissertation, I will use population level sequencing data to learn more about properties of 
mutation rate variation, selection and will infer several population genetics quotient of interest.  
Family based sequencing 
This approach entails sequencing of biological parents [16, 17] and their offspring, to find de novo 
germline mutations in the offspring. Typically, the exomes are sequenced for the entire family 
[102], but whole genome sequencing has become common due to increasing availability and 
better pricing [18]. The procedure involves (a) sequencing the family trio (mother, father and the 
child), (b) calling the polymorphic variants in all of them separately, and finally (c) finding the 
variants present uniquely in the offspring. The unique variants present in the offspring, but not in 
the biological parents are the de novo germline mutations. Studies with large scale sequencing of 
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family trios have reported an average of ~72 de novo mutations present in each offspring after 
sequencing of entire genome [16]. This corresponds to a genome-wide mutation rate of 1.2*10-8 
mutations, per nucleotide per generation. Similarly, this results in ~1 de novo mutation in each 
offspring after sequencing of entire protein coding genome [16, 90]. 
Typically, the blood is the DNA source of choice for most sequencing studies, because of ease of 
collection and quality of DNA. Hence, the de novo mutations identified in the offspring can also be 
caused by mosaicism [98], although with very less probability. However, for the purpose of 
analysis the community assumes it to be germline de novo. Moreover, the current strategy cannot 
distinguish recurrent from actual de novo mutations. Since, the probability of recurrent and the de 
novo mutation to happen at the same position is very low, the community considers all the new 
mutations in the offspring to be de novo.  
While family based sequencing is mostly used for finding de novo mutations in the offspring, there 
are additional advantages to family-based studies. First, family based sequencing allows for more 
accurate variant calling because of sampling of four independent alleles at each position, a total 
of six times (2 from each parent, and 1 from child and 2 copies in each). Since each variant in 
child is inherited from parents, with the exception of de novo events, this allows for more accurate 
joint variant calling in families. Second, it improves the ability to call variants in low coverage 
areas of the genome. Since less reads are available for accurate calling of variants in low 
coverage areas, joint calling of variants with the offspring significantly improves the sensitivity of 
the method to call variants with no effect on specificity. However, joint calling of variants has a 
high bar (more high quality reads in the child at the mutated site) for a variant to be reported as 
de novo, so it might also result in under calling of de novo variants in a family. Third and finally, 
family based sequencing allows for observation of inheritance of variants. Since, both the copies 
of the genome are sequenced in the entire family trio, this makes possible assigning the parent of 
origin status to each variant. 
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The community has mostly utilized family based sequencing approach to understand the process 
of mutagenesis [16, 17], for example understanding the relationship between paternal age and de 
novo mutations, or to investigate the role of de novo mutations in several pediatric diseases like 
Autism [90], Retinoblastoma [67], or Epilepsy [103]. While the former mostly entails genome-wide 
sequencing, hence the dataset are small, the latter involves mostly exome sequencing of larger 
samples.  
In this dissertation, I will utilize a family based sequencing dataset to validate my estimates for 
mutation rate variation. Moreover, I will use several de novo sequencing datasets of Autism and 
bilateral Retinoblastoma disease to find causal genes, testing specific, disease-relevant 
hypotheses. 
Thesis outline 
The central objective of this dissertation is to model the variability in the genome-wide rate of 
mutation and then leverage this variability to find causal gene and variants behind diseases, and 
test for specific disease hypotheses. A widely used yet unexplored idea in the field is, if sequence 
context models can explain variation in mutation rate, and furthermore do larger sequence 
context windows do better. Moreover, once the variability in mutation rate has been modeled, 
there is a lack of a systematic framework which can use this in several clinical applications. In this 
thesis, I address these open questions and challenges. 
In chapter 2, I evaluate different sequence context models and conclude that a larger 
heptanucleotide sequence context (which considers three nucleotides on either 5’ and 3’ end) 
around a polymorphic site explains significantly more variability in nucleotide substitution 
probabilities, in contrast to the commonly used trinucleotide sequence context (which considers 
one nucleotide on either 5’ and 3’ end). I use millions of variants from 1000 genomes[13] project, 
to find the substitution probabilities and show that they capture features of germline de novo 
mutation rate, identify several novel mutation promoting motifs at TACG, AT and CAAT sequence 
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contexts, and investigate the complex relationship between methylation intensity and higher CpG 
mutation rate.  
In chapter 3, I build on the substitution probability framework, and estimate the strength of 
selection at each sequence context in the coding genome. I use these estimates of selection to 
prioritize pathogenic variants and develop intolerance scores at gene and amino acid level for 
functional changes. Finally, I demonstrate how the intolerance scores can be used to prioritize 
genes for follow up from an Autism de novo sequencing dataset. 
In chapter 4, I develop a generalized approach to find enrichment of mutations at any sub-genic 
locus, beyond expected from a background model of mutation rate variation. I use this approach 
on a bilateral Retinoblastoma dataset to test for and discover regions in the RB1 gene with an 
unusual enrichment of de novo germline mutations, suggesting additional pathogenicity. I find that 
nonsense mutations in RB1 gene are enriched in RB ascertained probands and hence overall 
more pathogenic, but the previously identified higher number at CpG sites can be explained by 
higher background mutation rate, suggesting no additional pathogenicity at CpG sites compared 
to other nonsense mutations. Finally, I also test for and discover enrichment and hence more 
pathogenicity in specific splice-sites and missense mutations. 
In chapter 5, I estimate the de novo mutation rate at different sequence contexts using the 
substitution rates in chapter 2. I demonstrate that heptanucleotide mutation rate estimates 
accurately and best explain patterns of de novo mutations in an external dataset, in contrast to 
the commonly used trinucleotide context based mutation rate estimates. Finally, I use these rates 
to develop a toolkit to simulate, distribute and interpret de novo mutations in human diseases.  
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CHAPTER 2: Sequence context models and variability in substitution/mutation 
rates 
Introduction 
Measured at the level of the chromosome down to the individual base, rates of single nucleotide 
substitution vary substantially by position across mammalian genomes, including the humans [3]. 
An exquisite example of the role for sequence context in contributing variability in substitution rate 
are CpG dinucleotides, where spontaneous deamination of 5-methylcytosine results in ~14 fold 
higher C-to-T substitution rates [21, 104]. Modeling the variability in nucleotide substitution rates 
will inform our understanding of evolutionary processes, help identify functional noncoding 
regions [105] and mutation promoting motifs, reveal mechanisms behind spontaneous mutation, 
and aid in prediction of the clinical impact of polymorphisms discovered through resequencing 
[96]. Such models will need to determine not only the optimal window of local sequence context, 
but should also integrate knowledge of functional constraint on the genome owing to pressure 
from purifying selection. 
Studies of complex human disease have incorporated a simple trinucleotide sequence context 
[30, 106] into models to quantify the probability of de novo mutational events [33, 89], to clarify 
the distribution of somatic mutational events segregating in different cancers [32], and to model 
the purifying selective pressure on gene sequences [31]. As their focus was clinical, these reports 
did not determine if this context model best captured the extent to which flanking nucleotides 
impact the variability in genome-wide nucleotide substitution rates. Here, I report a statistical 
framework that compares the extent to which different local sequence lengths impact the 
probability of nucleotide substitution, tested using data from the 1000 Genomes (1KG) Project 
[13]. I define the probability of nucleotide substitution as the chance that a nucleotide in the 
human genome reference is polymorphic – i.e., the nucleotide position segregates alternative 
nucleotides within the population. This probability depends upon population history, selection, 
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sample ascertainment, and local context features that influence the rate of mutation. I show that a 
larger sequence context that considers 3 base pairs on either side of the polymorphic site 
(heptanucleotide sequence context) explains >81% variability in substitution and is significantly 
more informative than the commonly used trinucleotide sequence context. My approach 
discovers novel mutation promoting motifs at ApT dinucleotides, CAAT, and TACG sequences. I 
also identify previously undocumented variability in C-to-T substitutions at CpG sites, not 
immediately explained by differential methylation intensity. Finally, I show that the substitution 
probabilities, inferred over the intergenic noncoding region of the genome, capture features of 
germline de novo mutation rate. 
Data access 
Sourcing population samples 
Samples were obtained from phase 1 of the 1000 Genomes Project. Further details about sample 
collection, sequencing, and variant calling are available in the original publication [13]. I 
considered only the variants from African (n= 246 individuals), European (n = 379), and East 
Asian (n = 286) ancestries. 
Selection of intergenic non-coding sequences 
Intergenic sequenc [107] (Ensembl Genes 75 and Homo sapiens genes GRCh37.p13) and 
RefSeq Genes [108]. I initially removed centromeric, telomeric, and repetitive regions from these 
non-coding sequences by filtering out the contiguous sequences at the ends of the chromosomes 
and “gene deserts” of length greater than 2 MB. I also filtered away the sequences that were not 
present in the combined accessibility mask (version 20120824) of the 1000 genomes project. As 
a result, I was left with ~1100 Mb of autosomal intergenic regions and ~90 Mb on the X 
chromosome. Within these intergenic regions, I found 10,809,273 variants in the African 
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populations, 7,051,667 variants in the European populations, and 6,024,240 variants in the East 
Asian populations.  
Selection of HapMap variants 
Single nucleotide polymorphic variants were obtained from 2010-8 phase 3 release of the 
HapMap project [109]. I considered the variants from African ancestry only, belonging to 
populations YRI (Yoruba), LWK (Luhya), MKK (Maasai).  I also filtered for variants occurring in 
my intergenic non-coding sequences, resulting in a total of 1,659,929 variants. 
Methods  
Statistical framework to model substitution probabilities  
To explain my approach for modeling nucleotide substitution probabilities observed in a given 
population, I will first describe a simple model that does not take into account local sequence 
context, then build upon this simple framework by incorporating additional features to model 
nucleotide substitution probabilities in a way that considers the impact of local sequence contexts 
of varying lengths.  Suppose that we observe nC occurrences of nucleotide C in the reference 
genome. A subset of these nC sites will be polymorphic within the population of individuals. Let 
nCA represent the number of sites where a nucleotide change C-to-A has occurred. Similarly, nCG 
is the number of sites where a change C-to-G has occurred and nCT is the number of sites where 
a change C-to-T has occurred.  Then the probability of nucleotide substitution or polymorphism 
within the population genome-wide can be described at a given genomic site using a multinomial 
distribution: 
!
! ! !
1 	  (1)  
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where the probabilities of observing a substitution from C-to-A, C-to-G, and C-to-T are expressed 
as CA, CG, and CT respectively. After iterating over all possible substitutions (i.e., A-to-C, A-to-
G, A-to-T, C-to-A, C-to-G, C-to-T, T-to-A, T-to-G, T-to-C, G-to-A, G-to-C, G-to-T), I merged the 
reverse-complementary pairs (e.g., A-to-C was merged with T-to-G, etc.) to yield 6 “substitution 
classes” as parameters for the simple model, which I refer to as the “1-mer model”. This model 
can be naturally extended to consider the effects of local sequence context by replacing the count 
of nx occurrences of nucleotide X with the count of occurrences of a particular nucleotide 
sequence context. For example, if I want to consider the local sequence context ACA, then I 
count the number times nACA that this 3-mer sequence occurs in the reference genome. A subset 
of nACA will be polymorphic at the middle position C within a given population. Thus, let nACA→AAA 
represent the number of sites where a nucleotide change C-to-A has occurred at the middle 
position, nACA→AGA represent the number of sites where a nucleotide change C-to-G has occurred 
at the middle position, and nACA→ATA represent the number of sites where a nucleotide change C-
to-T has occurred at the middle position.  All of these combinations represent a 3-mer sequence 
context in which the polymorphic middle position is flanked by fixed nucleotides A on both sides. 
After merging reverse complementary sequences, there are 16 unique sequence contexts (e.g. 
four possibilities (A, C, G, or T) for the single fixed nucleotide located 5ʹ of the polymorphic site, 
and four possibilities for the single fixed nucleotide located 3ʹ of the polymorphic site) per 
substitution class. Across all six substitution classes, there are a total of 96 parameters estimated 
under this “3-mer model”. I analogously extend the size of the sequence context window to 
evaluate the “5-mer model” and the “7-mer model” by considering additional fixed nucleotides (2 
and 3, respectively) on either side of the polymorphic site, thereby estimating a total of 1536 
parameters for the 5-mer model and 24,576 parameters for the 7-mer model. For sake of 
comparison, I also considered a very simplistic null model that completely ignores sequence 
context and merges substitution classes into a single group, such that Equation 1 simplifies to a 
binomial distribution with a single estimated parameter. 
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Incorporating prior information into the nucleotide context models 
We may have some existing “prior” beliefs regarding probabilities of nucleotide substitution that 
can be incorporated into my framework using Bayesian statistics. For example, rates of 
nucleotide substitution in the coding genome should be proportional to, but not exactly the same 
as, the rates that are observed in the non-coding genome. This prior information can be 
incorporated into my model as follows. Because the likelihood of my framework is based on a 
multinomial distribution, I utilize its conjugate prior, i.e., the dirichlet distribution, for models that 
incorporate sequence context. For the null model, I can analogously utilize its conjugate prior, i.e., 
the beta distribution. For inference in the intergenic, non-coding genome, I selected the objective 
version of the prior for analysis, with all concentration parameters (or shape parameters for the 
analogous beta prior) of the dirichlet prior as 1. 
Log-likelihood ratio testing for model comparison 
To evaluate how increasing the length of the context sequence affects competing models’ fit to 
empirical data, I utilized a log-likelihood ratio testing procedure. First, the likelihood of the 
observed distribution of polymorphic sites given a specific sequence context model (null, 1-mer, 
3-mer, 5-mer, or 7-mer) was calculated using the substitution rate parameters estimated using all 
of the data. I calculate the likelihood ratio test statistic as: 
2 ln | 	 2 ln | 	                                        (2) 
where S1 and S2 represent parameters estimate from two competing sequence context models. 
The test is chi-squared distributed, with degrees of freedom equal to the difference in the number 
of parameters between the two models (e.g., comparing the 1-mer model versus the null model 
requires 5 degrees of freedom; comparing the 7-mer model versus the 3-mer model requires 
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24,480 degrees of freedom). Reported P-values are approximated analytically from the 
appropriate chi-square distribution using the R package (version 3.0.3). 
Bayes Factor analysis for model comparison 
I utilized the Bayes Factor approach, the Bayesian alternative to likelihood ratio testing, to 
contrast competing sequence context models against each other. I calculated the approximate 
posterior likelihood, using the Chib’s method, on the overall data using the maximum a posteriori 
(MAP) estimates of the substitution probabilities for a specific sequence context model (null, 1-
mer, 3-mer, 5-mer, or 7-mer) found before. I then calculate the approximate Bayes factor as: 
	 	 	
	 	 	
	
	 	 	 	
	 	 	 	                     (3) 
where S1 and S2 represent parameters estimate from two competing sequence context models. 
Since I use flat objective priors in the noncoding region and the MAP and MLE estimates are 
similar, the approximate Bayes factor reduces to the ratio of likelihood estimates under the two 
models. I use the Jefferey’s scale for interpreting the approximate Bayes Factors, where the ratio 
if greater than 100 is considered to be decisive evidence against the Model1. 
Regression modeling and feature selection 
I hypothesized that, within a substitution class (described above), the probability of polymorphism 
could be predicted using a linear combination of features based on the nucleotides at flanking 
positions within the 7-mer context. For the analysis below, I considered the posterior probabilities 
generated using data from the African group (1KG). I considered each substitution class 
separately and created an additional substitution class for each of the three possible changes 
within a CpG context (i.e., where the polymorphic 4th position nucleotide may change C-to-A, C-
to-G, or C-to-T, but the 5th position in the 7-mer context sequence is fixed as nucleotide G), 
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resulting in nine substitution classes that are taken into regression modeling. For each 
substitution class, I considered the initial regression model: 
→ | ⋯                                                     (4) 
where the probability that a nucleotide changes from X1 to X2 is modeled using a position-base 
variable p, a set of bases (e.g., {C, G, or T} where A is the reference base) denoted by the 
superscript for p, each position (= 1, 2, 3, 5, 6, or 7) denoted by the subscript for p within 
sequence context S, intercept , and error term . I assigned A as the reference nucleotide at 
each position and encoded the single nucleotide present at each position as the combination of 
three thermometer variables (e.g., 0,0,0 = A; 0,0,1 = C; 0,1,0 = G; 1,0,0 = T).  Position 5 is fixed 
as G for substitution classes within a CpG context, enabling us to remove position 5 terms from 
those models. Similarly, models of non-CpG classes considered only C and T bases at position 5. 
Next, I examined non-additivity (i.e., interactions) between nucleotides at sequence context 
positions. Rather than including all possible interaction terms, I employed feature selection (i.e., 
model training and testing to select the most informative features) and incorporated these terms 
into the final model. I considered 2-way, 3-way, and 4-way interactions across positions within the 
7-mer as: 
	 → | ⋯    
⋯ ⋯ ⋯            (5) 
where the probability that a nucleotide changes from X1 to X2 is modeled as described in 
Equation 4, and a set of additional terms related to interactions is also incorporated. Interaction 
terms are obtained from the product of thermometer variables p for bases w, x, y, or z (e.g., {C, 
G, or T} where A is the reference base) at positions i, j, k, or l (= 1, 2, 3, 5, 6, or 7). The effect of 
the interaction is represented by terms a for 2-way interactions, b for 3-way interactions, and c 
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for 4-way interactions. I only considered interaction terms that involved nucleotides located at 
different positions within the sequence context (i.e., i not equal to j, j not equal to k, and k not 
equal to l).  I divided the genome into two distinct sets for feature selection, using all even-
numbered chromosomes for training and all odd-numbered chromosomes for model 
testing.  During training, I performed stepwise forward regression for each level of interaction in 
order of increasing complexity (i.e., first 2-way, then 3-way, and finally 4-way). For each level of 
interaction, I further trained the model by sequentially incorporating interaction terms, one at a 
time, and evaluating whether each term improved the model using the ANOVA F-test. The most 
informative interaction term was added to the model at each step. I repeated this process until no 
additional features further improved the model (i.e., all proposed features were P > 0.001 by the 
F-test). For higher-order (3-way and 4-way) interactions, I ensured that a proposed feature 
maintained the hierarchy constraint (i.e., a selected 4-way term must bring with it all of its 
associated 3-way and 2-way terms). As a result of this constraint, when considering higher-order 
terms, I simultaneously considered any associated lower-order terms that had not been selected 
during prior lower-order training, thereby adding degrees of freedom to my F-test assessment. As 
my final model, I selected the trained model with the lowest mean-squared error, calculated via 8-
fold cross-validation within each substitution class. I report Akaike Information Criteria and 
adjusted-R2 values for the final model using the testing data set. Regression analysis was 
performed using R (version 3.0.3) using lm () for regression modeling, and the packages: leaps 
(v2.9), DAAG (1.20), lattice (v0.20-29), grid (v3.0.3), latticeExtra (v0.6-26), and RColorBrewer 
(v1.0.5). 
Sourcing CpG methylation data 
I obtained CpG methylation data for my intergenic regions of interest from a published whole 
genome bisulphite sequencing study performed on germline (sperm, oocyte) [110], blastocyst 
[110], blood [110] and brain [111] tissues. For each tissue, I divided the CpG sites into three bins: 
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(i) sites that were methylated in all samples, (ii) sites that were methylated in some but 
unmethylated in other samples and (iii) sites that were unmethylated in all samples. Very few 
sites fell into the second bin, so I excluded sites where methylation signal was inconsistent 
among the samples. I performed my analysis on the 7,059,740 intergenic CpG sites that were 
methylated and the 651,479 intergenic CpG sites that were unmethylated in all sperm samples. 
The same procedure was followed for samples from other tissues. I summarized the methylation 
signal across all samples for a tissue by calculating the mean intensity. 
Sequence Motif Identification 
I examined the top and bottom 10 sequences for each substitution class, and manually identified 
a total of 6 motifs that I tested in each substitution class, stratified by CpG context. This results in 
a total of (9 substitution classes) * (2 tails, high and low) * (6 motifs) = 108 total tests. Note that I 
required a nominal P = 4.6 x 10-4 (Bonferroni correction for multiple testing). I used Fisher’s exact 
test to find the P-value associated with the enrichment of specific sequence motif using the 
fisher.test function in the R package (version 3.0.3). The contingency tables for the test were 
populated by considering the enrichment of sequence motifs in the top or bottom 1% of 
substitution probabilities for that specific class of change.  
Sourcing recombination data 
I obtained recombination rate map of the YRI population from the phase 1 release of the 1000 
Genomes project 
(ftp://ftp.1000genomes.ebi.ac.uk/vol1/ftp/technical/working/20130507_omni_recombination_rates/
YRI_omni_recombination_20130507.tar), and segregated my intergenic non-coding regions of 
interest into high (recombination rate >3 cM/Mb) and low recombination rate (rate < 0.05 cM/Mb) 
regions. As a result, I considered ~203 Mb of intergenic non-coding sequence as belonging to 
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high recombination rate region and ~494 Mb of intergenic non-coding sequence as belonging to 
low recombination rate region.  
Human and primate divergence 
I obtained human-chimpanzee and human-macaque chain and netted alignments from the golden 
path directories in the UCSC genome browser 
(http://hgdownload.cse.ucsc.edu/goldenpath/hg19/vsPanTro4/axtNet/, 
http://hgdownload.cse.ucsc.edu/goldenpath/hg19/vsRheMac3/axtNet/) and found divergence 
between the human-primate pair by calculating fixed differences between the aligned intergenic 
non-coding sequences at each 7-mer sequence context. I was able to align 1.06 Gb of intergenic 
non-coding sequences between human-chimpanzee and 0.88 Gb between human-macaque. For 
each 7-mer sequence context, I calculated the divergence as the ratio of total number of fixed 
differences between the human-primate pair, and the total number of sequence context 
occurrences in the aligned region. 
Variants across the frequency spectrum 
I defined the rare variants as those occurring only once or twice in the population, and low or high 
frequency variants as those with MAF greater than 1%. I only considered the variants present in 
1000 genomes project belonging to the African ancestry and occurring in the intergenic non-
coding sequences, and found 2,789,383 rare and 8,019,893 low/high frequency variants.  
De novo mutations 
I only considered the de novo mutations from the high quality pedigree sequencing dataset of 
DECODE Genetics [16], that occurred in the accessible regions of the 1000 genomes project. 
This filtering was necessary because the original study did not describe the genome-wide regions 
that were “sequenceable”. I make an implicit assumption that atleast the accessible regions in the 
24 
 
1000 genomes project were sequenced in the original high quality pedigree sequencing study. I 
then found the observed de novo mutations for each motif class. The expected number of 
mutations occurring in each class was simulated under a normalized 1-mer sequence context 
model, such that the overall de novo mutation rate was fixed at 1.2 x 10-8 de novo mutations per 
generation and per sample. 
Results 
Heptanucleotide sequence context and variability in substitution probabilities 
I hypothesized that local sequence context –the nucleotides that flank a polymorphic site– could 
explain the observed variability in nucleotide substitution probabilities. To test this hypothesis, I 
defined a statistical model (Figure 2.1) whereby the probability that a nucleotide substitution 
occurs at a genomic site varies based on (i) the identities of the nucleotides that flank the site and 
(ii) the size of the 5′-to-3′ local sequence context window. To minimize the impact of natural 
selection, I focused on intergenic non-coding regions of the genome. As the estimated nucleotide 
substitution probabilities were robust (Table 2.1), I developed a likelihood-ratio testing procedure 
to evaluate competing local sequence context models. 
First, I calculated the likelihood of the observed data assuming a “1-mer” model, which allowed 
different substitution classes (e.g., A-to-G, C-to-T, etc.) to occur at different rates but ignored 
effects of sequence context on substitution probabilities. I compared the 1-mer model to the 
trinucleotide (“3-mer”) sequence context model where single 5′ and 3′ nucleotides flanking the 
polymorphic middle position impact the rate of substitution. As expected, the 3-mer model 
significantly improved fit to the data (log likelihood ratio, LLR = 6,070,948, P << 10-100, 
Supplementary File 2.1).  Next, I evaluated if additional local nucleotides could further improve 
fit to the observed data. Compared to the 3-mer model or the pentanucleotide (“5-mer”, or two 
flanking nucleotides), I demonstrate that the larger heptanucleotide (“7-mer”, three flanking 
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nucleotides) fit the data better (both LLR > 494,212, P << 10-100, Supplementary File 2.2). To 
further validate, I estimated substitution probabilities using 1,659,929 HapMap [109] variants 
found in my non-coding regions, and found that 7-mer context probabilities strongly correlated 
with probabilities estimated from 1KG data (Figure 2.2, Table 2.1), and provided the best fit to 
the observed polymorphisms (Supplementary File 2.3). My model recapitulates expected shifts 
in probabilities consistent with population histories [112] (Figure 2.3) and downward shift in the 
average substitution probability for the X chromosome [113] relative to autosomes (Table 2.2). 
Taken collectively, my analyses demonstrate for the first time that a 7-mer sequence context 
model explains the observed distribution of polymorphisms found in human populations. 
To incorporate prior information, I developed a Bayesian formulation using objective conjugate 
priors for analysis of the non-coding genome. Consistent with my previous analysis, the 7-mer 
context model proved superior compared to all other models (Approximate Bayes Factor (ABF) 
>> 1,000, Supplementary File 2.4). In subsequent analyses, I utilize these posteriors for the 
nucleotide substitutions probabilities. 
7-mer sequence context and variance explained in substitution probabilities 
To quantify the variance in the posterior probabilities that a 7-mer sequence context model could 
explain, I considered each substitution class separately, plus CpG site contexts (9 classes total). I 
employed forward regression to select features from a 7-mer context window to predict 
substitution probabilities, and considered up to four-way interactions at positions within the 
window. Compared to single-base and position models without interactions, incorporating higher-
order interactions substantially improved the fit to data (Supplementary File 2.5). Specifically, I 
found that my selected models in a separately held test data set explained a median of 81% of 
the variability (versus 30% from the 3-mer context) in probabilities across all substitution classes, 
covering 84% of all mutational events, and fitting well the probability of C-to-T substitution at 
CpGs (Table 2.3, Figure 2.4). While I identified a common set of interactions across classes 
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(Supplementary File 2.6), many common features did not always impact substitution 
probabilities in the same way, and others were class specific. These observations indicate that 
core and class-specific features based on sequence context are predictive of nucleotide 
substitutability. 
Methylation intensity and substitution probabilities at CpG sites 
The spontaneous deamination of 5-methylcytosine at CpG sites results in ~14-fold higher rates of 
C-to-T substitutions generally [28, 104]. Although a previous report indicated that divergence at 
CpG varies as a function of local context, the focus was on introns, and did not consider 
population-level polymorphisms in humans [114]. Thus, I hypothesized that surrounding 
sequence context further influences the probability of nucleotide substitution at CpGs, and 
examined the C-to-T substitution class within the subset contexts that contain CpG at position 4 
and 5 in the 7-mer. Simulations using a model that ignored additional genomic context, or 
considered the 3-mer context (Figure 2.5), using a fixed CpG substitution probability generated 
significantly less variability in 7-mer CpG substitution probabilities than was empirically observed 
(empirical P << 10-10, Figure 2.4). These data indicate that (i) not all CpG sites accrue 
substitutions at the same rate and (ii) that the sequence context surrounding CpG sites correlate 
with biological features or mechanisms that influence this rate. 
To explore the possibility that the excess variability depends upon variation in methylation 
intensity across sequence contexts, I reanalyzed whole-genome bisulfite sequencing data 
obtained from germline and other tissues of healthy individuals [110, 111]. Comparing the CpG 
sites that are consistently methylated versus consistently unmethylated across subjects, I 
observed as expected that methylation correlates with an increase in the probability of C-to-T 
substitution (P << 10-100, Figure 2.6). Unexpectedly, when I compared the methylation intensity in 
sperm at 7-mer CpG contexts with the probability of substitutions, I found a positive but imperfect 
correlation (R2 = 0.33, P < 10-90, Figure 2.7), with similar results in other tissues (Figure 2.8), 
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noting instances of methylation status decoupled from substitution probabilities. For example, 
nearly every genomic instance of the sequence contexts GTACGCA and GATCGCA showed 
consistent methylation signals (both methylated in >94% of occurrences in sperm), the probability 
of C-to-T transition was more than two-fold different for these two contexts (0.148 vs. 0.07, 
respectively). These data are consistent with the hypothesis that local context features beyond 
DNA methylation influence probabilities of C-to-T transitions at CpG sites, though I cannot 
exclude the possibility that sub-tissue methylation differences could explain these patterns. 
7-mer context model and novel mutation promoting motifs  
I next investigated the substitution probabilities for 7-mer contexts partitioned by substitution class 
(Figure 2.9, Supplementary File 2.7). First, I noted that several classes, C-to-A, and C-to-G in 
addition to C-to-T, appeared to segregate as mixtures of two distributions, explainable by CpG 
effects. These observations are consistent with studies demonstrating elevated substitutions at 
CpGs in humans [115], though this early work was not powered to measure context 
dependencies surrounding CpG sites as I am here. As the methylation transition state 
intermediate 5-formylcytosine can induce spontaneous C-to-A or C-to-G substitutions [116], one 
possibility is that methylation also elevates these rates in this context. I next determined if local 
sequence context motifs –analogous to but beyond CpG dinucleotides– correlate with variable 
substitution probabilities across classes. I noted that poly-CG sequences in the lower tail of C-to-
T substitutions for the CpG context were enriched (P < 10-16, Table 2.4). This observation is 
consistent with previous reports [117] as this context is found proximal to genes (Figure 2.10) 
and is associated with lower methylation intensities (Figure 2.11). In the upper tail of the A-to-T 
substitution class, I observed a poly-T+poly-A motif in the outlier sequences (P < 10-5, Table 2.4). 
I also observed a similar quad-A motif in the lower tail of the A-to-G class (P < 10-10). One 
possible mechanism that may contribute is the ‘slippage’ of protein machinery during DNA 
replication [118]. My analysis also revealed motifs without an obvious contributing mechanism. 
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First, in the upper tail of CpG rates, I observed enrichment of a TACG motif (P < 10-10, Table 2.4) 
that was strongly methylated (Figure 2.11), but curiously, a similar motif shifted by one position 
was enriched in the lower tail of the A-to-C class (P < 10-4). Second, the ApT dinucleotide was 
found to elevate the substitution probabilities (Figure 2.9) for the A-to-G (P < 10-25) and A-to-T 
classes (P < 10-17), though not statistically significantly so for A-to-C. Finally, I observed a CAAT 
motif also enriched in the upper tail of the A to G substitution class (P < 10-53), reported in an 
earlier study of dbSNP variants [119]. These latter cases indicate potentially new mechanisms 
contributing to elevated nucleotide substitutability, not documented by the commonly utilized 
trinucleotide context model. As a final robustness analysis, keeping in mind limitations due to 
variant ascertainment, I estimated the substitution probabilities using HapMap variants and found 
similar mutation promoting motifs across substitution classes (Table 2.5).  
Substitution probabilities and germline mutation rate 
If the estimated non-coding substitution probabilities reflect properties of mutation, one would 
expect that these rates should (a) not influenced by rates of recombination (assuming 
recombination is not mutagenic) (b) strongly correlate with rates of species divergence [120], (c) 
be consistent for both rare and common genetic variants, and (d) also be reflected in de novo 
mutational events. I explored each of these predictions in turn. First, I estimated the 7-mer 
substitution rates from all intergenic non-coding variants separately for high and low 
recombination rate regions, and found a strong correlation between the two (R2 = 0.97, P << 10-
100, Figure 2.12), indicating that substitution probabilities estimated from the non-coding genome 
are consistent across high and low rates of recombination. Next, using human-chimpanzee and 
human-macaque alignments over intergenic non-coding sequences, I found a strong correlation 
between divergence and substitution probabilities for my 7-mer contexts (both R2 = 0.96, P << 10-
100, Figure 2.13, Table 2.6). I then estimated 7-mer probabilities from all intergenic non-coding 
rare variants (singletons and doubletons) separately from low and high frequency variants (>1%), 
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and found a strong correlation (R2 = 0.98, P << 10-100, Figure 2.14), as well as a superior 7-mer 
context fit to data across variant frequencies (Supplementary File 2.8). Finally, I obtained 4,748 
de novo mutational events from a high quality pedigree sequencing dataset on 78 parent-
offspring trios [16]. I tested for the presence of motifs I identified in Table 2.4 around de novo 
events, and observed a significant enrichment (Table 2.7). Taken collectively, these findings 
provide additional validation for the hypothesis that my substitution probabilities capture features 
of germline mutation.  
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CHAPTER 3: Substitution rates in the coding genome and clinical applications 
Introduction 
The genetic variation spectrum in protein coding regions, unlike intergenic noncoding regions is 
strongly affected due to forces of selection [121]. While purifying selection mostly purge 
deleterious variants which have an effect on fitness, other types of forces like balancing [44] or 
positive selection [122] also act on the coding genome. Therefore, the community has 
hypothesized and demonstrated that genes and variants with strong selective pressure on them, 
are more likely to be pathogenic and confer higher risk of disease [47]. An accurate model of this 
overall selective constraint, can aid in prioritization of genes and variants discovered from exome 
sequencing of different diseases [96], and also elucidate the differential evolutionary processes 
acting on the genome.  
Previous approaches for variant prioritization either measure fixed differences in the genes 
between related species by comparative genomic approaches [123], changes to protein structure 
[124], deviation in frequency spectrum from neutral distribution [125] or combination of all of these 
[126]. While these are highly informative, they do not directly measure the overall selective 
constraint unique to human lineage and at the resolution of sequence context. A recent approach 
[31] aims to measure the selective constraint on genes as a function of local sequence context, 
but is limited in resolution. In the previous chapter, I demonstrate that a larger heptanucleotide 
sequence context explains more variability in intergenic substation probabilities, which captures 
features of de novo germline mutation. Here, I build on that framework and model substitution 
probabilities in the coding region as a function of sequence context and also estimate selective 
constraint. I show that a larger heptanucleotide sequence context model best explains patterns of 
polymorphisms in the coding genome, and identify previously unappreciated variability in the 
coding substitution rates. Next, I model a function of the selective constraint acting on the coding 
genome as a function of sequence context, by comparing the intergenic substitution probabilities 
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which are mostly shaped due to mutational forces with coding substitution probabilities which are 
shaped both by mutation and selective forces. I then develop several clinical utilities which can 
prioritize variants and genes identified from disease sequencing studies. 
Data Access 
Sourcing of coding sequences 
I selected exonic coordinates of the longest transcript for each gene annotated in ENSEMBL 
Biomart (Ensembl Genes 75 and Homo sapiens genes GRCh37.p13). I only considered those 
transcripts where (i) the total exonic region length was a multiple of 3, and (ii) 90% or larger of it 
was present in the combined accessibility mask (version 20120824) filter of the 1000 Genomes 
project. For all genes of interest, I used phase information to map each genomic coordinate to a 
specific position on a codon, yielding 16,386 autosomal transcripts and 679 transcripts from the X 
chromosome.  
To test my model in a different data set, SNP sites for ~4300 individuals of European ancestry 
were obtained from large-scale independent exome sequencing studies generated by the NHLBI 
GO Exome Sequencing Project, from the Exome Variant Server [92] (EVS, 
http://evs.gs.washington.edu/EVS/, downloaded on August 26th 2013).  
Annotation of SNP variants in the autosomal coding genome 
For 1KG data, I manually annotated the type of codon change caused by each variant, yielding 
92,893 synonymous, 110,645 missense, and 1,639 nonsense variants (total n = 205,282) for the 
African group. I repeated the same strategy for the non-Africans, resulting 64,756 synonymous, 
89,863 missense, and 1,591 nonsense variants (total n = 156,298) within the European group 
and 58,304 synonymous, 80,689 missense, and 1,378 nonsense variants (total n = 140,450) 
within the Asian group. For the EVS data (European ancestry), I also manually annotated the type 
of codon change, yielding a total of 226,833 synonymous, 388,149 missense, and 15,287 
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nonsense variants (total n = 636,122) distributed over the coding regions of interest. To obtain a 
representative spectrum of allele frequencies (and impact of background selection) observed 
from the smaller set of individuals found in the 1KG data, I considered only EVS variants with 
frequency greater than 0.03% resulting in a total of 169,659 variants.  
Sourcing information about pathogenic variants 
I used the Human Gene Mutation Database [58] (HGMD professional 2014.4) to identify 
pathogenic variants for my autosomal genes of interest, which supplied 60,504 variants 
distributed over 3,647 genes for 5,359 putative human disorders. 
Methods 
Extension of the substitution probability framework for coding regions 
To model substitution probabilities for the coding genome, I utilized the statistical model 
developed for intergenic regions with the following modifications: First, I accounted for codon 
position-effects (i.e., a given sequence context around a polymorphic site may occur at three 
different positions on a codon), which can lead to amino acid changes that may be subject to 
different levels of selective constraint. To model this phenomenon, I considered the probabilities 
for each of the three possible codon positions separately, resulting in a total of 73,728 (3 * 
24,576) parameters for the 7-mer context model. Second, I utilized probabilities learned from the 
intergenic non-coding region model as my Bayesian prior for the coding model. The parameters 
for this prior include the baseline probabilities from the intergenic noncoding region as shape 
parameters for the dirichlet distribution, multiplied by an additional normalizing weighted constant, 
per the following: 
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→ ∗ 	 → ∗ 	 → ∗                             (1)                    
where p represents the intergenic noncoding substitution probability from sequence context S to 
each possible polymorphic change (1, 2, 3, or 4 represent each possible nucleotide base at the 
site), n is the number of occurrence of the context S in the coding region. This choice of shape 
parameter in the prior allowed for inference of coding substitution probabilities, while utilizing the 
intergenic substitution probabilities, and without the prior overwhelming the evidence observed in 
the coding region. 
Scaling the model for use with a larger data sample  
As the number of individuals sequenced increases, the observed number of polymorphic sites 
segregating within the dataset will also increase. To calibrate my model (built using the 1KG 
dataset) for use with the larger EVS dataset, I rescaled the substitution probabilities estimated 
using 1KG data to make them proportional to the EVS dataset. I used a constant scaling factor 
defined as:  
	 	 	 	 	 	
	 	 	 	 	 	 	
                                      (2) 
on all substitution probabilities in the new dataset. 
Bayes Factor analysis for model comparison in the coding region 
I utilized the Bayes Factor approach, the Bayesian alternative to likelihood ratio testing, to 
contrast competing coding sequence context models against each other. I compared the 7-mer 
model with codon position effects and priors from noncoding region as described before, against 
the basic 3-mer model with no codon position effects and with a flat objective prior. The 
approximate posterior likelihood, using the Chib’s method, on the overall coding data was then 
calculated using the maximum a posteriori (MAP) estimates of the substitution probabilities for the 
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two coding sequence context models as found before. I then calculate the approximate Bayes 
factor using Equation 3 from Chapter 2. For the 7-mer model the probability of parameters is 
found using the dirichlet distribution function in the gtools (v3.4.1) package in R (v3.0.3). Since I 
use flat objective priors in for the 3-mer model so the probability of parameters reduces to 
calculating the normalizing beta function in the dirichlet distributions. I use the Jefferey’s scale for 
interpreting the approximate Bayes Factors, where the ratio if greater than 100 is considered to 
be decisive evidence against the Model1. 
Simulating variability in substitution probabilities within all AA classes 
To simulate the distribution in variability for substitution probabilities within different amino acid 
substitution type, I randomly distributed the number of observed substitutions within the type 
using a fixed rate model. I then calculate the respective 7-mer probabilities using my multinomial 
distribution model for the randomization, and use those to tabulate the variance across different 
amino acid substitution types. 106 simulations are used to generate the distribution of substitution 
probabilities. 
Measuring the effects of selection on the probability of polymorphism  
To minimize the effects of selection on initial estimates of substitution probabilities, I selected 
intergenic non-coding intervals for model development. Assuming that the mechanisms that 
introduce new mutations into coding regions are similar to those at work in the non-coding 
genome, I inferred that the relative ratio of coding-to-non-coding substitution probabilities could 
indicate natural selection occurring in the coding genome. Furthermore, I expected that the rates 
of certain types of amino acid change should be less frequent than others (e.g., on average, I 
expect to observe non-synonymous changes less frequently than synonymous changes) as a 
result of background selection. To quantify the effect of selection on substitution probabilities, I 
measured the log10 ratio of coding-to-non-coding substitution probabilities using all coding 
variants (n = 205,282) observed in the 1KG African group. Estimates for coding substitution 
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probabilities were uncertain under certain conditions, owing to a limited number of a given variant 
type for a particular 7-mer context. Thus, rather than use my MAP estimates for these sequences 
contexts, I simulated the substitution probabilities from the beta distribution using a 3-mer context 
model extended to the coding region. I then calculated the log-ratio of the intergenic non-coding 
substitution probability to the mean obtained from simulation. 
Calculating tolerance scores for genes 
Using my estimates for substitution probabilities in the coding genome, I performed simulations 
using the standard multinomial distribution for each sequence context to define the distribution of 
polymorphism levels expected for each gene based on my model. I then normalized the 
difference between the observed levels of polymorphism and those generated from my 
simulations, to obtain gene tolerance score defined as: 
	 	
	
                               (3) 
where NS and NS represent the mean and standard deviation of nonsynonymous 
polymorphisms generated from simulations based on my model, and nNS is the empirical number 
of nonsynonymous polymorphism observed in the data. A positive gene score in Equation 3 
indicates that the number of observed substitutions is fewer than expected, and serves to identify 
genes experiencing stronger than average purifying selection. In my analysis, I determined gene 
scores for the African, European, and EVS populations.  
Categorizing genes 
I subdivided genes into various categories – i.e., essential genes (where the mouse homolog 
knock-out is lethal), ubiquitously expressed genes, genes with known phenotypes described in 
OMIM, immune-related genes, keratin genes, olfactory genes and those belonging to several 
neuropsychiatric diseases. The dataset from [127] was used to find the first two categories, while 
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[125] was used to classify OMIM genes. OMIM sub-categorizes genes according to mutational 
models, including de novo, dominant, haploinsufficient, or recessive. In my analysis, I merged 
OMIM’s de novo, dominant, and haploinsufficient categories, treating them as a single category. I 
used the DAVID ontology database [128] (version 6.7) to classify immune-related, keratin, and 
olfactory genes. I considered the gene list published in the latest de novo sequencing analysis 
papers of Autism [52], Epilepsy [103], Intellectual disability [129–131] and Developmental 
disorder [132], as the gene set belonging to these diseases. I merged the gene lists of the 
aforementioned diseases, treating them as single category belonging to “All Neuropsychiatric 
disease”.    
AUC comparison between competing gene scores on different gene sets 
I used the receiver operating characteristic (ROC) curve to compare the performance of my gene 
scores against previously annotated scores [31, 125] for classifying genes into the gene sets I 
described above. Since, the Petrovski et. al. scores were originally released for HGNC gene ids, I 
was only able to convert 16,910 genes out of a total of 16,957 to corresponding ids in ENSEMBL 
format. Similarly, the Samocha et. al. approach only identified 1,003 genes to be intolerant and 
released their scores for Refseq gene ids, so I was able to map 997 genes only to corresponding 
ids in ENSEMBL format. Moreover, for a uniform comparison between different approaches, I 
only considered the previously annotated scores for autosomal genes that I identified before (i.e., 
which passed the stringent quality criteria of sequencing in the 1000 genomes project). I fitted a 
linear classifier using the three different gene scores, on each gene set and found the area under 
the curve (AUC) for each. The linear model was fitted using the glm function (with binomial family 
parameter) in R (v3.0.3). The performance of the models on different gene sets was evaluated 
using the pred and performance functions (with auc as a parameter) using the ROCR (v1.0-5) 
package. 
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Calculating tolerance scores for amino acids 
Using my estimates for substitution probabilities in the coding genome, I performed simulations 
using the standard multinomial distribution for each sequence context to determine the expected 
number of changes for a specific amino acid within a given gene. Within a given gene, I 
normalized the difference between the observed numbers of amino acid changes at a specific 
codon versus the number of changes expected from simulation using the equation:  
	 	
	
                   (4) 
where AA and AA represent the mean and standard deviation of the specific amino acid 
replacement polymorphisms generated from simulations based on my model, and nAA is the 
empirical number of amino acid replacement polymorphisms observed in the data. I consider the 
normalized value in Equation 4 as the final tolerance score for that amino acid within the given 
gene. I interpret a positive amino acid (AA) tolerance score to indicate that the observed number 
of changes for that specific amino acid within the given gene was even fewer than expected. 
Thus, the AA tolerance score serves to identify amino acids experiencing stronger than average 
purifying selection. Moreover, since the AA scores measure the tolerance of a gene at an amino 
acid level, they further improve the resolution of the gene scores, which measure the overall 
tolerance in a gene. In my analysis, I determined AA tolerance scores for the African population. 
Application of Gene and Amino acid scores on Autism de novo mutations 
I used the de novo sequencing data for Autism spectrum disorder [90], to test the efficacy of my 
gene and amino acid score approach in identifying and prioritizing novel genes and variants 
associated with Autism. I found the de novo mutations belonging to cases and controls separately 
for each of my genic sequences of interest and further classified them into synonymous, 
missense, nonsense, splice and indel categories only. As a result, I considered a total of 2,171 
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mutations in 2,508 cases and 1,421 mutations in 1,911 controls, belonging to my genic 
sequences of interest.  
For a uniform comparison of gene scores across different approaches [31, 125], I only considered 
the top 752 intolerant genes identified from each approach. I choose 752 genes because this was 
the number of intolerant genes identified in [31], which mapped to my autosomal genic 
sequences of interest (i.e., which pass the stringent criteria of sequencing quality in the 1000 
genomes project). I used the Odds ratio to find the burden of de novo mutations in cases as 
opposed to controls, in the set of intolerant genes. Fisher’s exact test was used to compare the 
significance of burden.  
The amino acid scores was found on known Autism genes identified in the latest de novo 
sequencing paper [52], and compared with (a) all mutations in controls or with (b) all mutations in 
cases belonging to non-Autism genes. All statistical comparisons were performed using the 
Wilcoxon sum ranked test. Similar analysis was also performed on genes with a higher burden of 
functional (missense, nonsense changes for which amino acid scores are generated) de novo 
mutations in cases as opposed to controls. 
Results 
7-mer sequence context and variability in exonic substitution probabilities  
Assuming that the processes that generate spontaneous mutations apply uniformly across the 
genome, I hypothesized that sequence context could explain variability in substitution 
probabilities in the coding genome. I therefore extended my initial framework (Figure 2.1) to the 
coding genome by (i) using information obtained from my model on the non-coding genome as 
prior and (ii) allowing for context dependence of codons and local sequence context in my 
estimates of substitution probabilities to accommodate purifying selective pressure [121]. My new 
model substantially improved the fit to the data compared to either 3-mer sequence context 
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models with or without codon context (ABF >> 1,000, Table 3.1). To further validate, I tested my 
model on a different large scale exome-sequencing dataset from ~4,300 individuals [92], and 
noted that my 7-mer model fit patterns of exonic polymorphisms better than competing models 
(ABF >> 1,000, Table 3.1). These results demonstrate for the first time, that a broader sequence 
context –beyond simple codon or trinucleotide context– captures the forces that shape variability 
in nucleotide substitutions in the coding genome.  
I then examined the posterior distribution of substitution probabilities for all contexts stratified by 
the type of amino acid substitution (Figure 3.1, Supplementary File 3.1), and found excess 
variability in each class than expected under simulation (Supplementary File 3.2). Next, I 
enumerated the substitution probability profiles for each amino acid change, and found certain 
nonsense and missense substitution probabilities to be higher than synonymous levels (Figure 
3.2), partially explained by CpG contexts. These observations caution against the practice –
invoked in rare-variant association tests– of ignoring codon and sequence context when testing 
for the burden of functional substitutions. My results here demonstrate that functional 
substitutions may not be equally likely or tolerated with respect to purifying selection.   
Application: 7-mer context model and power to identify pathogenic variants 
I now turn to applications of my model to improve the interpretation of variation discovered by 
clinical re-sequencing. Efforts to prioritize variants from such studies often rely on classifying 
variants that are deleterious with respect to population genetic fitness, hypothesizing that such 
variants are more likely pathogenic [133]. As my coding substitution probabilities are influenced 
both by forces of mutation (estimated from the non-coding genome) and selection, I hypothesized 
that the ratio of these probabilities quantifies the action of selective pressure, and could be used 
to prioritize pathogenic variants. To test this hypothesis, I calculated the log ratio of intergenic 
non-coding and coding substitution probabilities, defined as sequence constraint score, for 
missense (n = 48,450) and nonsense (n = 12,054) variants present in the Human Gene Mutation 
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Database [58] (HGMD). I observed that the distribution of sequence constraint scores for HGMD 
variants was shifted towards larger values (intolerance) compared to 1KG variants (P << 10-100, 
Figure 3.3), compatible with the “intolerant variant, pathogenic variant” hypothesis. Moreover, the 
distribution of scores based on my 7-mer model was further shifted towards intolerance with a 
thicker tail, compared to a 3-mer model (P << 10-100, Figure 3.4). These data demonstrate that a 
coding model that includes codon and a 7-mer context improves identification of variants that are 
potentially pathogenic.  
Application: Gene scores for intolerance to functional changes 
Several groups have argued that the power to identify causal disease genes from clinical 
resequencing data could be enhanced by incorporating estimates of selective constraint on genes 
[31, 125, 127]. The underlying hypothesis behind this concept is that genes that are under 
selective constraint are more likely to have functional consequences and are therefore most likely 
to be pathogenic and have fewer functional variants (“intolerant gene, pathogenic gene”). The 
community has successfully applied this concept to neurodevelopmental and psychiatric 
disorders [134], however the existing approaches have not incorporated the 7-mer sequence or 
codon context in their models. 
Therefore, I applied my 7-mer coding substitution probabilities to develop an intolerance score 
(Supplementary File 3.3) quantifying the difference between the expected and observed number 
of functional variants at a gene, with higher scores consistent with functional constraint. To further 
validate, I found gene scores on a separate, larger exome sequencing data set and observed a 
strong correlation between the two (Figure 3.5). I found that genes belonging to putatively 
essential or ubiquitously expressed categories, scored strongly for genic intolerance (P << 10-100, 
Figure 3.6). In contrast, gene sets representing Keratin and Olfactory categories were found to 
be highly tolerant of functional changes (Figure 3.6). Next, I applied this to OMIM genes or 
known genes behind several neuropsychiatric disorders like Autism [52], Epilepsy [103], 
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Developmental disorder [132] and Intellectual disability [129–131], and found them to have 
significantly higher intolerance scores (P << 10-100, Figure 3.6). I then compared my gene scores 
to previously reported scores (Figure 3.7), and found that my approach improved classification or 
performed comparably to other approaches [125] for genes in each set, including the disease 
categories (Table 3.2). These results demonstrate that the most accurate scoring of genic 
tolerance to functional substitution can be achieved by modeling 7-mer sequence and coding 
context. 
Application: Amino acid intolerance scores and prioritization of pathogenic variants 
Beyond the average rate of amino acid replacement that a gene might tolerate, genes could be 
further intolerant to specific types of amino-acid substitutions, signifying added localized selective 
constraint or importance for gene functionality. Therefore, I developed a score measuring the 
intolerance at amino acid replacement level in a gene (Supplementary File 3.4), after quantifying 
the difference between the expected and observed number of functional variants for a specific 
amino acid at a gene. Across all genes represented in HGMD with a large number of putatively 
pathogenic amino acid changes for a specific substitution, I found they segregate larger 
intolerance scores for that amino acid (empirical P < 10-10). Moreover, a gene might score 
“tolerant” for functional substitution, but intolerant for specific amino acid changes. For example, 
Von Willebrand Factor (VWF), a blood glycoprotein involved in hemostasis, is tolerant to 
substitution overall (within top 8% of gene tolerance) but intolerant to cysteine substitution (within 
top 3.5% of cysteine intolerance). This data is consistent with a causal mechanism for von 
Willebrand disease; protein misfolding when cysteine residues are substituted [135]. Here, I note 
that 5,652 genes segregate a profile similar to VWF: average genic tolerance, but amino acid 
intolerance. 
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Application:  Interpretation of de novo mutations discovered in Autism 
Autism spectrum disorder is a disease with complex etiology, and recent efforts have aimed to 
identify de novo mutational events that may contribute to disease. To highlight the utility of gene 
[31, 125] and amino-acid scores, I applied them to interpret de novo mutations collected from 
2,508 Autism spectrum disorder [90] cases and 1,911 control family trios. First, I found that the 
most intolerant genes based on my gene score segregated a significant burden of de novo 
mutations in cases as opposed to controls (OR = 1.66, P < 0.0004, Figure 3.8), even after 
removing known autism genes [52] (OR = 1.54, P < 0.001), and similar, though slightly attenuated 
burden using other scores (Figure 3.8). Next, I found that the average amino acid scores for de 
novo mutations at Autism genes in cases was higher (more intolerant) than that found in controls, 
or at other genes in cases (P = 0.002, Figure 3.9). I further observed higher (intolerant) average 
amino acid scores for variants in genes with a positive variant burden in cases, relative to controls 
(+2 or +3 allele count excess in cases, both P < 0.01, Figure 3.9). Finally, several genes from the 
excess allele count set stood out with amino-acid specific intolerance (all within top 4 percentile of 
intolerance): MYO9B, WDFY3, NAV2, STIL, and SCUBE2. Aside from WDFY3, these genes are 
generally ‘tolerant’, based on their gene-score, indicating utility of sub-gene wise measurement of 
functional intolerance. While MYO9B has been implicated in autism [52] and WDFY3 deletions in 
a murine model has been shown to cause Autism like symptoms [136], my analysis points to the 
remaining candidates for future follow-up.  
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CHAPTER 4: Understanding RB pathogenesis using a mutation rate modeling algorithm  
Introduction 
Retinoblastoma (RB) is a cancer of the developing retina and occurs in both hereditary (~45% of 
cases) and sporadic (non-hereditary) forms [60]. The hereditary form of RB with the distinctive 
clinical features of bilateral tumors and a younger age at diagnosis is associated with the 
presence of germline mutations in the tumor suppressor retinoblastoma 1 (RB1) gene [137]. 
Knudson proposed a “two hit” model for the hereditary forms of RB: the first hit comprises a 
germline mutational event present in all cells; the second, an additional somatic genetic event 
within a retinal cell, overall which results in bi-allelic inactivation of RB1 [64]. Germline mutation 
can either be transmitted or occur de novo in the affected proband with bilateral RB. Unlike 
transmitted variants which are present in the previous generation, de novo germline mutations 
can arise prior to conception on one of the parental genomes, or occur post-conception during 
early embryonic development [138].  
Studies of de novo mutations in bilateral RB offer a new lens in which to understand the 
pathogenicity of specific classes of mutations. For the most part, previous studies have focused 
on transmitted germline mutations or mutations in bilateral probands not confirmed as de novo. 
These studies have substantially advanced our understanding of RB pathophysiology and clinical 
interpretation of new mutations by identifying regions or domains within RB1 with the greatest (or 
least) mutational burden [67, 68, 139, 140]. However, transmitted variants themselves may not 
always reflect truly pathogenic mutations, owing to allele frequency differences across human 
populations (i.e., admixture) [141]. Moreover, de novo mutational studies allow complete 
discovery of the spectrum of novel mutations that may occur in a single generation. Thus, studies 
of de novo germline mutations offer additional, orthogonal information toward understanding the 
mutational processes and associated pathogenic burden of new mutations that ultimately result in 
RB [6]. One current, open question is if de novo mutations occur uniformly over RB1, or instead 
44 
 
localize to specific codons, sequence contexts, or protein domains. Based on Knudson’s model, 
we expect a higher frequency of de novo mutations that result in putative loss-of function (LoF) in 
RB1 in patients ascertained for RB, which has been previously shown [67]. Numerous studies 
have reported that the preponderance of nonsense mutations occur at CpG sites in RB1 [67, 68, 
70, 140], with one study documenting a 90-fold higher rate of nonsense mutations at CpG 
transitions compared to non-CpG transversions in RB1 of bilateral RB patients [70]. These 
observations could suggest a role of CpG sites in generating nonsense mutations [142], with 
deamination of hyper-methylated CpGs proposed as a mechanism to explain this “apparent” 
excess [139, 143, 144]. However, an alternative model could explain the observed frequency 
simply by disease ascertainment of loss-of-function mutations coupled with the high mutability of 
CpG sites due to deamination events [3]. In addition, numerous splice-site mutations have also 
been observed in RB1 [68, 140, 145], many of which have been shown to result in exon skipping 
[145]. However, it remains to be quantified if all of these events are equally pathogenic. Finally, 
point mutations have been observed as frequently mutated at specific codons, which includes 
R661W [71, 72, 146]. This codon falls within the pocket domain in RB [147], an important domain 
that facilitates binding of RB1 with downstream targets to regulate cell cycle. However, to my 
knowledge, enrichment of mutations at this or other codons in RB1 has not been statistically 
quantified.  
Investigating these questions for RB has been limited by the lack of a statistical model that 
captures mutation rate variability in human genomes at base-pair resolution. In the following, I 
utilize my previous work on models for nucleotide substitution using local sequence context, 
which explains a substantial fraction of variability in mutation rates observed in human 
populations [29]. I report a generalized algorithm to measure the enrichment of mutations beyond 
what is expected from this model, at base pair resolution. Using this approach, I performed exon- 
and sub-exon-level de novo mutational burden analysis to quantify the relative frequency of 
nonsense, splice-site, and missense mutations across RB1, in contrast to previous approaches 
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[67, 70, 139] that mostly binned the mutations into categories and reported simple abundance. I 
show that the previously reported excess of nonsense mutations in RB1 at CpGs is compatible 
with the elevated rate of mutation at those sites, refuting a specific pathogenic mechanism in RB. 
Moreover, I report the enrichment of essential splice-site donor mutations at exon 6 and 12, but 
depletion at exon 5, indicative of previously unappreciated heterogeneity in relative penetrance 
across this type of putative LoF mutation. Finally, my approach confirms a statistically significant 
excess of mutations found at R661W in bilateral RB, as a hotspot for missense mutations with 
lower penetrance.  
Data access 
Patient samples 
Patients included in this study were recruited as part of a research protocol between 1998 and 
2011 from pediatric oncology clinics within North America. The de novo mutations presented here 
were identified from 642 children in the Genetic Diagnostic Laboratory at the University of 
Pennsylvania. These samples represent bilateral RB cases without family history, and where both 
parental DNA sample was available. Parental DNA samples were tested for the mutations 
identified in the respective affected child to rule out familial cases, and to unambiguously 
establish the presence of de novo mutational events. Of the 75 sporadic bilateral cases identified 
previously [66], only 23 samples overlap (i.e., had parental samples also submitted/available). 
The Institutional Review Board of University of Pennsylvania approved our screening protocol. 
DNA isolation and Sequencing 
The isolation of DNA, PCR amplification of RB1 sequences, and Sanger sequencing of amplified 
PCR products was performed as previously described [66]. Primer sequences used for 
amplification are available on request.  
RB1 genic sequence region 
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I considered the genic sequence of RB1 with accession number L11910 in the GENBANK 
database. Only exons 2 to 27 in RB1 were analyzed; exon 1 was excluded to the presence of a 
cryptic start site [70, 148]. I also analyzed 50 base pairs on both 5’ and 3’ ends of the exon. Six 
base pairs on the 3’ end of the exon were defined as donor essential splice sites, while 2 base 
pairs on the 5’ end were defined as acceptor essential splice sites. The remaining nucleotides, 
from position 7 to 50 on the 3’ end of the exon, and from 3 to 50 on the 5’ end of the exon were 
defined as intronic sites. As a result, I analyzed a total of 5,460 nucleotide bases in the gene, out 
of which 2,787 were from protein coding region, 2,457 intronic and remaining 216 belonging to 
essential splice sites.  
RB mutational data 
A total of 571 mutations were identified, which included 289 point mutations. Furthermore, I 
considered missense, nonsense, essential splice, and intronic mutations that falling in the RB1 
sequence region defined per the above, that passed quality control. As a result, 268 mutations 
falling in my region of interest were analyzed. 
ExAC variants 
I only considered the singleton variants (missense, nonsense, essential splice and intronic) in the 
non-Finnish European populations from the ExAC dataset. I initially downloaded all variants in 
“ENSG00000139687” gene id from ExAC, including only mutations that were observed once 
(singletons). As a result, I analyzed 149 singleton variants falling in my region of interest as 
described above.   
RB mutational data from collaborators 
I independently received nonsense mutational data from a recent publication of germline de novo 
mutations in RB [70]. I analyzed 100 variants from this dataset that were present in my region of 
interest as described above. 
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LOVD variants 
I queried the variants present in the 2015 release of the Leiden Open Variation Database (LOVD: 
http://rb1-lsdb.d-lohmann.de/variants.php?action=search_unique&select_db=RB1) for in the RB1 
gene. I only reported the results from the point mutations present in the database. 
Methods  
Analysis of the total number of mutations discovered 
Unlike the noncoding region, previous studies [16] have reported a higher de novo mutation rate 
of ~1.5 x 10-8 mutations per base pair per generation in the coding region. Since I consider a total 
genomic territory of 5,460 nucleotide base pairs in RB1 gene and sequenced 642 individuals (or 
1,284 haploid chromosomes), I expect a total of 0.1 de novo mutations in our sample. This is 
calculated by multiplying the de novo mutation rate (1.5 x 10-8) with the total genomic territory 
(5460 base pairs) and total number of haploid chromosomes sequenced (642 x 2). Since, I 
observed 268 non-silent de novo mutations and I expect 0.1 de novo mutations, I report extreme 
statistical significance after simulations from a Poisson distribution with fixed parameter as the 
expected mean of 0.1.  
Analysis conditional on a set of observed mutations  
The majority of analyses presented in the paper focused on generating the expected number 
(and variance in) mutation number, conditioned on a specific type of event or sub-sequence with 
RB1 where a set of events had occurred. In the case of mutations identified in RB probands, this 
involved distributing all (or a subset of) n=268 de novo mutations we discovered by re-
sequencing RB1. For the comparison to ExAC, this involves distributing all (or a subset of) n=149 
singleton variants I identified in non-Finnish Europeans, as an admittedly imperfect proxy for de 
novo events. My procedure involved three steps: 
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Step One: Select genomic territory and observed mutations that fall in region of interest. For 
results where n=268 mutations were distributed, I considered all of the available genomic territory 
that was re-sequenced and filtered from my discovery effort (i.e., a total of 5,460 bases, as 
described above). Here, if the base pair position did not result in a desired type of mutation, that 
base is excluded. The number (and type) of mutations that are subsequently distributed was 
based on those actually discovered within the specified territory. Finally, I assumed de novo 
mutations located in any/all positions in my territory was always able to be discovered, if present.  
Step Two: Distribute mutations on sequence according to context model. The probability of 
mutation at each base pair of the genomic territory selected in Step One is provided by my 7-mer 
sequence context based substitution probabilities, which were estimated from the non-coding 
genome in my prior work [29]. Briefly, a nucleotide base can change into one of three other bases 
(e.g., nucleotide C can change to A, G, or T) with different substitution probabilities based on the 
type of change. Depending on the codon and position context, this nucleotide change can result 
in one of many types of coding changes (e.g., nonsense, splice-site, etc.). The type of mutations 
selected in Step One determines which of these three nucleotide base changes at the position is 
considered. For example, if only nonsense mutations were selected in Step One, I would consider 
only the base pair positions and subset of possible nucleotide changes in each base pair that 
result in a nonsense mutation. Once all probabilities across base pairs have been identified, I 
then normalize by the sum of all probabilities so that the total at all eligible bases where a change 
could occur in the gene is 1. For a given simulation and the total number of mutations selected in 
Step One, each is distributed across the gene from a multinomial distribution with probabilities as 
estimated before.  
Step Three: Determine Empirical Significance. For each comparison, I performed 1,000,000 
simulations to determine the empirical distribution of mutation count found at the type or sub-
sequences of mutations specified in Step Two. Empirical p-values for significant enrichment 
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(deficiency) were determined by counting the number of times that the simulations had a value 
greater (less) than or equal to the observed number of mutations in that class.  
Rates of different classes of mutation, relative to nonsense mutations 
I first calculate the ratio of observed to expected mutations in a category after distributing all 268 
de novo mutations at all eligible bases and possible changes (any change except those resulting 
in a synonymous mutation) using my algorithm described before. Next, I normalized this ratio by 
dividing it with the mean for nonsense category. This results in setting the mean of observed to 
expected variants for nonsense category as 1. I then plot the mean and standard error of this 
ratio for each category of mutations. The different distributions of this observed to expected rate 
are compared using a standard 2 sample t-test. 
Results 
Re-sequencing of sporadic bilateral RB patients  
To quantify the role of de novo mutations in the pathophysiology in RB, we re-sequenced RB1 in 
642 cases presenting sporadic (i.e., without family history), bilateral RB and their parents. The 
targeted resequencing included all exons of RB1 as well as 50 base pairs of intronic sequences 
on either side of exons. For statistical modeling purposes, I focused on single base point 
mutations and excluded individual who carry a frame-shift or in-frame insertion-deletion 
mutations. After variant calling followed by quality control, I identified 276 de novo germline, 
single base point mutations. Owing to an alternative start codon in exon 1 [70, 148], my 
subsequent analyses focus on the remaining exons, resulting in 177 amino-acid altering 
mutations, 86 in essential splice-sites, and 5 mutations found in introns outside of essential 
splice-sites (total of 268 de novo events, Supplementary File 4.1). Consistent with the causal 
role of RB1, the discovery of 268 de novo mutations in 642 RB probands is highly unusual 
(Expected number of variants = 0.1, P << 10-10). Furthermore, I observed more nonsense and 
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essential splice-site mutations than missense or intronic mutations, expected given the 
pathogenic nature of loss-of-function (LoF) mutations in RB1 (Table 4.1). For a population-level 
comparison, I contrasted my mutational profile to the data obtained from the Exome Aggregation 
Consortium (ExAC) [149], consisting 60,706 individuals re-sequenced for the exome. Here, I note 
that ExAC excluded childhood diseases from their aggregation, which may have excluded RB 
patients. As a result, I do not expect this sample to represent a completely random population 
sampling of mutations in RB1. From ExAC, I focused on singletons observed in non-Finnish 
populations of European ancestry (n=149 variants in >33,000 subjects, Supplementary File 4.2). 
Consistent with samples from ExAC as population-level controls with potential ascertainment 
against RB disease, I observed fewer loss-of function and more missense and intronic variants 
compared to the de novo mutations identified in RB probands (Table 4.1). 
An algorithm to quantify the enrichment of de novo mutations  
My central objective is to determine if the frequency, type, and location of de novo mutations in 
RB1 were consistent with the number of events predicted from my local, nucleotide sequence 
context model for mutation rate variability. For example, I expect more nonsense mutations in RB 
patients than my background model predicts, because (i) I ascertained individuals with RB, (ii) 
nonsense mutations are likely LoF, and (iii) LoF at RB1 causes RB. To achieve this objective, I 
require an accurate model that captures variability in the frequency of de novo mutational events 
across RB1 and an engine to distribute mutations in RB1 according to this model. With these in 
place, I can empirically assess significance of enrichment of de novo mutations in exons or sub-
sequences of RB1 relative to my model prediction.  
In my previous work [29] I demonstrated that an expanded sequence context model which 
considers three flanking nucleotides on either side of a base (i.e., heptanucleotide), explains 
variation in germline mutation rate better than competing models of sequence context, and up to 
93% of the variability in substitution probabilities. Using the sequence context based substitution 
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probabilities, I developed an algorithm to distribute mutations across the gene in order to 
generate an expected count of mutations (with variance) at all positions in RB1 (Figure 4.1). With 
these distributions in hand, I can estimate the empirical significance conditioned on the observed 
number of any type of substitution in any sub-sequence(s) within the gene. As an imperfect 
control, I use singletons from ExAC (allele frequency of ~1/66,000, ~0.00152%) in which to 
compare our de novo events, with the assumption that these events are the youngest and have 
not experienced the full force of purifying selection; i.e., are the closest proxy to de novo events 
segregating in (non-Finnish) European populations. In what follows, I apply my approach to study 
(i) the overall frequency of nonsense, essential splice-site, and missense mutations in RB1 and 
ExAC, and (ii) their spatial occurrence by exon or by sub-sequence (CpG sites, domains, or 
codons).  
Abundance of nonsense mutation at CpG sites explained by elevated mutation rate 
I first investigated if nonsense mutations were distributed proportionally to the predicted rate of 
mutation, or alternatively localize to specific sequences, like CpGs. As a positive control, I first 
distributed the 268 identified mutations ascertained in RB probands and determined how many 
nonsense mutations were predicted from my sequence context mutational model. I found an 
enrichment of nonsense mutations beyond that expected from my model (P << 10-6, Figure 4.2). 
This observation is consistent with extensive literature showing that LoF mutations at RB1 cause 
RB. As a negative control, I distributed variants identified from the ExAC database, and observed 
fewer nonsense mutations than expected based from my model (P = 0.0103, Figure 4.2). This is 
also expected, as I anticipate few (if any) nonsense mutations in RB1 observed in the general 
population or in ExAC participants which may have excluded RB patients.  
I next examined if the subset of 150 nonsense mutations I observed were unusually distributed 
across exons in RB1. I found that, across virtually all exons, nonsense mutations occurred as 
frequently as my model predicts, broadly consistent with the concept that nonsense mutations 
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found across RB1 are similarly pathogenic (Figure 4.3). The single exception was exon 27, which 
segregated fewer mutations than my model predicted (P << 10-6, Figure 4.2). This observation is 
compatible with the hypothesis that nonsense mutations in exon 27 are not fully penetrant, 
perhaps due to incomplete nonsense mediated decay [150] or that this exon may not be integral 
to the etiology of RB. Previous studies have observed fewer mutations at later exons in the RB1 
gene [67], though they were unable to quantify the reduction and assess statistical significance as 
I am able to do here. While I observed fewer mutations at exons 25 and 26, these numbers are 
still compatible with my background mutational model, given the number of mutations that were 
discovered in re-sequencing. 
Next, I examined if the subset of 150 nonsense mutations I observed were unusually distributed 
in amino acid type or codon contexts across RB1. I found that the distribution of de novo events 
by amino acid and codon context was not especially different from what my mutational model 
predicted (Table 4.2). Specifically, my model predicted a large number of C-to-T transitions 
resulting in Arginine to Stop mutations at the CGA codons (93 observed, 99% CI: 73 – 104, P = 
0.24), presumably due to the higher mutational frequency at the CpG context [3, 30]. This 
analysis indicates that observed profile of nonsense mutations can be explained simply by the 
background rate of mutation, without a need to invoke a RB-specific mutation-promoting or 
pathogenic mechanism at CpG sites.  
To replicate these observations, I repeated my analysis on an independent set of 100 nonsense 
de novo germline mutations in RB1 of bilateral RB patients (Supplementary File 4.3). These 
results recapitulated the observed deficiency of nonsense events in exon 27, and my model also 
matched the number of nonsense mutations at CpG sites or at CGA codons relative to other 
nonsense sites (Tables 4.3 and 4.4). 
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Excess splice-site donor mutations in introns 6 and 12, but depleted in intron 5 
I next investigated if essential splice-site and intronic mutations were distributed proportionally to 
the rate of substitution predicted by my context model. As a positive control, I distributed the 268 
mutations ascertained in RB probands and determined how many essential splice-site and 
intronic mutations were expected from my sequence context mutational model. I found more de 
novo essential splice sites mutations in RB patients than predicted (P << 10-6, Figure 4.3). This 
observation is consistent with the idea that essential splice-site mutations that are LoF at RB1 
cause RB. As a negative control, I distributed variants identified from the ExAC database and 
observed fewer essential splice variants there (P = 0.014, Figure 4.3). This is not unexpected: 
analogous to nonsense mutations described above, I anticipate few essential splice-site 
mutations in the general population and/or ascertainment against RB patients in ExAC 
participants. In intronic sequences that are found outside of essential splice sites, I observed 
substantially fewer events in RB patients than my model predicted (P << 10-6, Figure 4.3). In 
contrast, I found more intronic events in ExAC than my model would predict (P << 10-6, Figure 
4.3). Taken collectively, these two observation suggest weak (if any) overall pathogenicity for 
intronic mutations outside of essential splice-sites. 
I then examined if the 86 essential splice-site mutations I ascertained in RB probands were 
unusually distributed across introns in RB1. First, I found that essential splice-site acceptor 
mutations were not unusually distributed (Figure 4.4), so I focused on the remaining 63 essential 
splice-site donor mutations. Next, I observed no mutations in the donor site of intron 5, which was 
outside my model prediction (P << 10-6, Figure 4.5). However, this observation is readily 
explainable: if we assume that essential splice-site donor mutations here result in exon skipping 
as seen for other splice-site mutations [145], it turns out that skipping exon 5 retains the coding 
reading frame, albeit with a 13 amino acid deletion (Figure 4.6). Therefore, this type of mutation 
may not result in full LoF of the RB1 protein product, and thus, may be weakly penetrant, if at all. 
Next, I found that essential donor splice-site mutations in intron 6 and 12 segregated more 
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mutations than my model predicted (P << 10-6, Figure 4.5). Previous studies [68, 140] have 
observed that exon 6 and 12 mutations are recurrently mutated in RB1, though they were unable 
to quantify the enrichment and assess statistical significance as I are able to here.  
It is not immediately apparent why these specific splice-site mutations are enriched in RB 
ascertained patients compared to other splice donor mutations. Essential donor splice-site 
mutations at intron 6 and 12 result in exon skipping [145], out-of frame shift mutation, and 
putative LoF (Figure 4.6). However, essential donor splice-site mutations at other introns (except 
intron 5) also result in frame-shift mutations in RB1 if exons are skipped. To further validate the 
observation of specific enrichment at these exons, I utilized the Leiden Open Variation (LOVD) 
Database [151] (Methods), a curated catalog of mutations found in RB1. Because variants are 
reported from multiple studies, where the gene territory re-sequenced and total number of 
individuals ascertained is not completely documented, I am limited in my ability to statistically 
quantify variant enrichment in LOVD as I can for our RB data. I found recurrent mutations with 
multiple reported variants (or fewer for exon 5) even in the LOVD database of all reported 
variants in RB1 gene of patients with RB (Table 4.5). Moreover, the donor sequences of inton 6 
and 12 also are similar to other canonical splice sequences found at other (not enriched) exons. 
Taken collectively, these data suggest some additional pathogenic burden of these mutations 
relative to other essential splice-sites in RB1.  
Localized enrichment of missense mutations to R661W in RB1 
I investigated if missense mutations were distributed proportionally to the rate of substitution 
predicted by my context model. I distributed the observed 268 mutations across the gene, and 
found significantly fewer missense mutations than expected (P << 10-6, Figure 4.7). This 
observation is consistent with the model that missense mutations as a class generally are less 
penetrant for RB, contrasting against the substantially higher penetrance of LoF nonsense or 
essential splice mutations. In contrast, ExAC participants were not unusual in the distribution of 
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missense variants observed relative to my model prediction (P = 0.041, Figure 4.7). Taken 
collectively, these data suggest that, as a class, missense mutation in RB1 are less frequently 
pathogenic than nonsense variants and result in fewer mutations ascertained in RB probands.  
The idea that missense mutations generally are less penetrant for RB1 still leaves open the 
possibility of heterogeneity in pathogenicity among sub-sequences of RB1. For example, R661W 
is a frequently observed mutation found in families that segregate lower penetrance [71, 72, 146]. 
Computational prediction tools like Polyphen2 [124] or evolutionary conservation based metrics 
[152] are frequently used to rank missense variants categories of deleteriousness as a proxy for 
pathogenicity. I applied Polyphen2 to classify all missense mutations we identified, and found 
most of them to be damaging (Table 4.6).  
To further improve the resolution of these predictions, I applied my approach to identify a smaller, 
statistically credible subset of missense mutations implicated in RB pathogenicity. To achieve 
this, I distributed all 27 missense mutations I ascertained in RB probands across RB1 to 
determine if these rates were proportional to my predicted mutational model. I observed a 
significant enrichment of missense mutations in exon 20, mapping to the known pocket domain in 
RB1 (Figure 4.8, 8 mutations out of 27, P << 10-6). Although the pocket domain in RB1 gene 
encompasses other exons [71, 147] (i.e., Pocket Domain Box A: Exons 13-17, Pocket Domain 
Box B: Exons 18-22), I did not observe a specific enrichment of missense mutations there (all P > 
0.01, Figure 4.8). I next distributed the missense mutations within the pocket domain territory in 
RB1 (n=18 missense mutations in 307 codons across the entire pocket domain). I observed an 
excess of missense mutation burden within exon 20 in Pocket Domain Box B near codon 661 
than predicted by my model (P << 10-6, Figure 4.9).  
I next sought to localize the signal of the missense mutational burden within exon 20. I distributed 
all missense mutations I observed within exon 20 (n=8 in total), and observed an enrichment of 
missense mutations from CGG to TGG coding for a change from Arginine to Tryptophan (Table 
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4.7). Specifically, I found the previously observed recurrent mutation R661W (n=5 times in my 
sample) occurred more frequently that my model predicted (P << 10-6). Here, I note the limited 
resolution of Polyphen2, as it also predicts other sites nearby as damaging (Table 4.6).  
To place this observation in context of other missense mutations documented in RB1, I evaluated 
the frequency of n=130 missense mutations in exon 2 to 27, curated by the LOVD repository. 
There, the most frequently cataloged missense mutation was R661W (n=33 of 127), with the next 
most frequently listed as C712R (n=8 of 127), G137D (n=6 of 127), and T307I (n=5 of 13). 
However, when reflected against ExAC, R661W was observed only once (<0.001%) and C712R 
was not observed at all, consistent with putative pathogenicity of both variants. In contrast, 
G137D and T307I were far more frequent in ExAC (0.04% and 0.3%, respectively), suggestive of 
very low RB penetrance for these events. While the LOVD ascertainment is certainly complex 
and precludes me from formally evaluating statistical significance, these data are consistent with 
the importance of R661W as pathogenic and a frequently mutated position. 
Relative rates of different classes of mutations found in RB1 
Finally, I sought to quantify – relative to nonsense mutations – the rates of various sub-types of 
de novo mutations I observed in RB1. Assuming the penetrance of nonsense mutation is nearly 
full, the idea here is that if a subtype of de novo mutation was as penetrant as nonsense 
mutations, I would expect to have ascertained that subtype as frequently as nonsense mutations, 
proportional to the mutability of the subtype. I found that the rate of ascertainment of essential 
splice-site mutations was statistically lower than nonsense mutations (P << 10-10, Figure 4.10), 
consistent with the lower penetrance of essential splice mutations due to some less pathogenic 
changes observed at the essential splice positions (e.g., intron 5). Similarly, the rate of intronic 
and missense mutations relative to nonsense was substantially smaller (P << 10-10, Figure 4.10). 
Finally, while the rates of missense mutations found in both Pocket Domain Box A and B were 
less frequent relative to nonsense mutations, I noted that mutations localized to Box B were more 
57 
 
frequent compared to missense mutations overall or in Box A (both P << 10-10, Figure 4.10). 
Together, these data suggest a mixture of penetrant missense mutations found across RB1, 
elevated in penetrance for Box A mutations, and further elevated in Box B, the Box that also 
contains codon 661.  
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CHAPTER 5: A framework for interpreting de novo mutations in human disease 
Introduction 
Mutation creates genetic variation between individuals, and is critical for understanding 
population history [15], estimating evolutionary distances between species[9], detecting natural 
selection [153] and for discovering causal genes and variants[31, 125, 154] behind genetic 
diseases. Previous studies [3, 30], including ours [29] have reported significant variability in the 
mutation rate across the genome, and at the level of local sequence context around the 
polymorphic site. A striking example of the local sequence context in influencing the rate of 
mutation, is the spontaneous deamination of 5-methylcytosine at methylated CpG sites which 
causes a ~15-fold elevated C-to-T mutation rate relative to the genome [28]. Recently the 
community has tried to understand and measure the role of de novo mutation burden in several 
childhood disorders like Autism [52, 89], Epilepsy [103] and Congenital heart disease [53] to 
identify causal genes. All existing approaches [155, 156] for measuring this mutation burden at 
the genic level require an accurate estimate of mutation rate which captures the variability, and a 
systematic framework to model, measure and test for the burden of de novo mutations in affected 
probands. 
Previous methods to estimate variability in the germline mutation rate can be broadly categorized 
into the phylogenetic [157, 158] or the parent-offspring sequencing [16] approach. The 
phylogenetic approach considers the neutral mutations (mostly silent mutations at few pseudo-
genes) between humans and other hominid species and then under the molecular clock 
assumption find the coarse estimates of mutation rate. Family trio sequencing approaches, which 
measure the de novo mutations in each generation of a family, have higher resolution and are 
more accurate than phylogenetic estimates, but are still severely underpowered owing to sparsity 
of de novo mutations identified in each generation (only ~70 per parent-offspring trio). Recently, 
several studies have also estimated de novo mutation rate from millions of SNPs in the intergenic 
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noncoding region, which are mostly shaped due to forces of mutation [31, 89], to accurately 
capture the variability in the mutation rate. However, they use a less informative sequence 
context model for mutation rate estimates, and also a simplistic framework to model and test for 
burden of de novo mutations in affected cases. Here I address these challenges by developing a 
systematic framework to estimate de novo mutation rate at different competing sequence context 
models from millions of SNPs from 1KG dataset [13]. I demonstrate that a larger heptanucleotide 
sequence context based de novo rate estimates best explain variability in mutational data. I also 
report a higher mutation rate estimate for the coding genome and finally develop a systematic 
framework that allows the user to simulate or distribute de novo variants over genomic regions.  
Data Access  
De novo mutations  
I only considered the de novo mutations from the high quality pedigree sequencing dataset of 
DECODE Genetics [16], that occurred in my defined whole genome accessible territory. This 
filtering was necessary because the original study did not describe the genome-wide regions that 
were “sequenceable”. I make an implicit assumption that at least the accessible regions in the 
1000 genomes project were sequenced in the original high quality pedigree sequencing study. As 
a result, I finally considered 4,748 de novo germline variants over 2.53 GB of autosomal genomic 
territory from sequencing of 156 haploid chromosomes (or 78 individuals) for my analysis. 
Whole genome territory  
We assumed that the accessible regions (combined accessibility mask (version 20120824) of the 
1000 genomes project) from the 1000 genomes project were “sequenceable” and of high quality. 
As a result, we considered 2.53 GB of autosomal genomic territory for analysis. 
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Intergenic non-coding region 
Intergenic sequences were defined as the full set of genomic sequences that are not annotated in 
ENSEMBL Biomart [107] (Ensembl Genes 75 and Homo sapiens genes GRCh37.p13) and 
RefSeq Genes [108]. I further removed genomic regions 10 KB upstream and downstream of all 
such coding annotations. This is to further ensure that regulatory regions enriched near the genic 
annotations, and are subjected to forces of selection [46] are not considered in our analysis. 
Finally, I intersected this set of regions with the accessibility mask filter of (combined accessibility 
mask, version 20120824) of the 1000 genomes project to find the high quality set of 
“sequenceable” intergenic non-coding regions. As a result, I considered 0.83 GB of autosomal 
intergenic noncoding genomic territory for our analysis. 
EVS variants 
To test my de novo sequence context rates in the coding region, I only considered variants from 
the EVS data which occurred as singletons or doubletons, hypothesizing that these variants may 
have not been subjected to full forces of selection and represent the closest proxy to de novo 
mutations in the coding genome.  
Coding transcripts 
I selected exonic coordinates of the longest transcript for each gene annotated in ENSEMBL 
Biomart (Ensembl Genes 75 and Homo sapiens genes GRCh37.p13) and RefSeq Genes 
database. I considered transcripts where the total exonic region length was a multiple of 3. For all 
genes of interest, I used phase information to map each genomic coordinate to a specific position 
on a codon, yielding 16,342 autosomal transcripts and 711 transcripts from the X chromosome. 
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Methods 
De novo rates estimation 
As previously described in my work in Chapter 1 and in a recent publication [29], I first found the 
intergenic substitution probabilities from the 1000 genomes Phase 1 [13] data over our defined 
intergenic noncoding regions of interest. Within these intergenic regions, I found 7,504,983 single 
nucleotide polymorphic variants in the African populations and 4,878,890 variants in the 
European populations. Since, intergenic substitution probabilities are (a) mostly shaped due to 
forces of mutation and (b) I have further removed regions upstream and downstream of genes 
compared to our previous analysis where I showed that substitution probabilities capture 
properties of de novo germline mutation, so I assume here that these latest intergenic substitution 
probabilities also capture variability in mutation rate. 
Next, I developed an approach to estimate de novo mutation rate at each sequence context from 
the substitution probabilities inferred before. Since substitution probabilities are a constant scalar 
multiple of de novo mutation rate, we can estimate this scalar multiple by fixing the overall de 
novo mutation rate to 1.2*10-8 mutations per base pair per generation. In Equation 1, I present 
our approach to find this scalar multiple.  
_ ∑ _
	
_	
∑ _	
1.2 10                (1) 
We can solve for the scalar multiple by plugging in the substitution probabilities and the 
corresponding counts at each sequence context. The overall idea behind this is that ratio of 
genome-wide expected mutations to genome-wide territory is the overall genome-wide de novo 
rate of mutation. We can find the overall genome-wide expected mutations by multiplying the 
mutation rate at a context (scalar multiple of substitution probabilities) to its number of 
occurrences. Similarly, we can find the overall genomic territory by summing the counts of all 
sequence contexts. Here, I note that my approach is generalizable and I can estimate the de 
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novo mutation rate at each sequence context with any other overall estimate of mutation rate. Our 
substitution probabilities, capture the relationship between mutation rate at different sequence 
contexts, and can be normalized with any overall estimate to find sequence context specific 
mutation rate estimates. 
Comparison of competing sequence context models 
Whole Genome comparison: To evaluate how increasing the length of the context sequence 
affects competing models’ fit to the test data, I utilized a log-likelihood comparison procedure. We 
trained and estimated different sequence context based de novo germline mutation rates from the 
1KG dataset and tested their fit on a separate de novo germline mutational dataset [16], of 4,748 
mutations from sequencing of 78 family trios. The likelihood of the observed distribution of de 
novo mutations given a specific sequence context model (null, 1-mer, 3-mer, 5-mer, or 7-mer) 
was calculated using the statistical framework, I described before [29] in Chapter 1. I will first 
describe here a simple model that does not take into account local sequence context, then build 
upon this simple model by incorporating additional sequence context features. Suppose that we 
observe nC occurrences of nucleotide C in the reference genome. A subset of these nC sites will 
have a de novo germline mutation in our sample. Let nCA represent the number of sites where a 
mutation C-to-A has occurred. Similarly, nCG is the number of sites where a mutation C-to-G has 
occurred and nCT is the number of sites where a mutation C-to-T has occurred.  Then the 
probability of de novo mutation within our sample after sequencing n haploid chromosomes can 
be described at a given genomic site using a multinomial distribution: 
∗ !
! ! !
1 	  (2)  
where the probabilities of observing a mutation from C-to-A, C-to-G, and C-to-T are expressed as 
CA, CG, and CT respectively. This model can be naturally extended to consider the effects of 
local sequence context by replacing the count of nx occurrences of nucleotide X with the count of 
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occurrences of a particular nucleotide sequence context. For example, if I want to consider the 
local sequence context ACA, then I count the number times nACA that this 3-mer sequence occurs 
in the reference genome. A subset of nACA will have mutation at the middle position C within the 
sample. Thus, let nACA→AAA represent the number of sites where a mutation C-to-A has occurred 
at the middle position, nACA→AGA represent the number of sites where a mutation C-to-G has 
occurred at the middle position, and nACA→ATA represent the number of sites where a mutation C-
to-T has occurred at the middle position. All of these combinations represent a 3-mer sequence 
context in which the middle position is flanked by fixed nucleotides A on both sides. I analogously 
extend the size of the sequence context window to evaluate the “5-mer model” and the “7-mer 
model” by considering additional fixed nucleotides (2 and 3, respectively) on either side of the 
polymorphic site. Using this framework, I calculate the likelihood of different sequence context 
models on the test data of de novo germline mutations. 
Coding Genome comparison: I further tested the de novo germline estimates of the exonic 
region on my defined coding transcripts. However, this test was performed on our defined EVS 
variants occurring in the coding transcripts. I first scale the de novo germline mutation estimates 
by a constant multiple, specific for each sequence context model, such that the overall number of 
expected variants is the same as total number of EVS variants (n = 702,935) observed in our 
sample. The total number of expected variants is calculated using Equation 3,  
∑ 	 	 	 _	                      (3) 
with counts calculated on my defined coding territory. Then, I use the likelihood comparison 
procedure defined above, to find the likelihood of competing sequence models on the EVS data. 
The rates are all scaled by the constant multiple, counts are calculated on my defined coding 
region and counts of mutations are the EVS variants observed in our sample. 
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De novo mutation rate in coding region 
I find the de novo mutation rate estimate in the coding region by finding the ratio of total expected 
mutations in my defined coding region to the total nucleotide count there. The total expected 
mutations are calculated as defined above. I multiply the de novo mutation rate estimate at each 
context to its count in the defined coding region to get the total expected mutations. 
I also find the de novo mutation rate specific to the type of change (synonymous, missense, 
splice, nonsense, specific amino acid) in the coding region by incorporating codon structure in my 
model. First, I classify each sequence context change into the desired category of substitution 
(i.e. it results in a change like synonymous mutation or at a specific amino acid), and then I 
multiply its sequence context mutation rate with its total occurrence in the category. I then sum 
this multiple for all eligible sequence contexts and divide it by the total count of nucleotides to find 
the de novo mutation rate specific to a substitution class.  
Simulation of de novo mutation 
In my toolkit SimDenovo, I simulate de novo germline mutations over any genomic region queried 
by the end user, and output the total and individual category specific expected mutations over 
that region. The user enters the number of haploid chromosomes n over which k simulations 
need to be performed. The central idea is to find the total expected mutations over any genomic 
region, after sequencing n haploid chromosomes. 
For any such genomic region, I first find the total count of each heptanucleotide sequence context 
in the genomic region, and also multiply the mutation rate at each heptanucleotide sequence 
context with the n haploid chromosomes entered by the user. Next, I use the previously defined 
multinomial statistical framework to simulate mutations at any sequence context over k 
simulations. For each simulation, I find the number of mutations from a heptanucleotide sequence 
context to another. Finally, I assign the simulated mutation (for all k simulations) at a sequence 
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context, to any randomly chosen occurrence of that sequence context in the genomic region, and 
classify it into a specific category (missense, nonsense, synonymous, amino acid or CpG etc.). 
The final output to the user includes summary statistics of total and individual category specific 
simulated de novo germline mutations. 
Distributing of de novo mutation 
In my toolkit SimDenovo, I distribute n de novo germline mutations over any genomic region 
queried by the end user, and output the total and individual category specific expected mutations 
over that region, based on the background rate of mutation. The user enters the total number of 
de novo mutations n that need to be distributed over the genomic territory after performing k 
simulations. The central idea is to find expected mutations in each sub-category in the genomic 
region conditional on observing a total of n mutations. 
My procedure for distributing mutations first involves finding the probability of mutation at each 
base pair of the genomic territory. A nucleotide base can change into one of three other bases 
(e.g., nucleotide C can change to A, G, or T) with different mutation probabilities based on the 
type of change. Once all probabilities across base pairs have been identified, I then normalize by 
the sum of all probabilities so that the total at all bases where a change could occur in the 
genomic territory is 1. For a given simulation and the total n number of mutations, each is 
distributed across the genomic territory from a multinomial distribution with probabilities as 
estimated before. Finally, I classify the mutation into a specific category (missense, nonsense, 
synonymous, amino acid or CpG etc.). The final output to the user includes summary statistics of 
individual category specific distributed de novo germline mutations. 
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Results 
Accurate and Informative estimates of de novo mutation rate 
I hypothesized that a sequence context based approach using millions of SNPs from population 
level sequencing data (1000 Genomes project [13]) could be used to infer the variability in de 
novo mutation rates. To test this hypothesis, I built on my previous work [29] and defined a 
statistical model where the substitution probabilities were inferred for windows of different 
sequence context length, from population level SNPs over intergenic non-coding regions far away 
from genes to minimize the impact of selection. I then normalized the substitution probabilities to 
get mutation rate estimates at each sequence context, such that the genome-wide de novo 
mutation rate is fixed at 1.2 x 10-8 mutation per site per generation [16]. Since the de novo 
germline mutation rate is similar across humans [3, 8], I further hypothesized that the mutation 
rates inferred from polymorphism data across different populations result in similar estimates. In 
order to test this hypothesis, I robustly estimated the de novo mutation rates at hepta-nucleotide 
(“7-mer”, three flanking nucleotides on either side) sequence context windows from the African 
(Supplementary File 5.1) and European (Supplementary File 5.2) populations from the 1000 
Genomes project and found the rates to highly correlated and similar (R2 = 0.996, Pearson 
correlation = 0.998, Figure 5.1).   
Next I evaluated the performance of my mutation rate estimates on 4,748 de novo events from a 
high quality pedigree sequencing dataset from 78 Icelandic parent-offspring trios [16]. I compared 
the observed and the expected de novo mutations under different substitution classes, and found 
that my de novo estimates accurately predicted the distribution under each class (Table 5.1). In a 
previous work [29], I discovered several novel mutation promoting motifs at ApT dinucleotides, 
CAAT and TACG motifs. Here, I also found an enrichment of de novo mutations at these motifs 
and my mutation estimates to accurately predict the distribution under each motif class (Figure 
5.2, 5.3). Taken collectively, my analyses demonstrate that a sequence context based approach 
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using polymorphisms from population level sequencing dataset can be used to accurately 
estimate the de novo mutation probabilities at a fine scale. 
My previous work [29], also showed that the larger heptanucleotide (“7-mer”, three flanking 
nucleotides) sequence context around a polymorphic site, explained significantly more variability 
in genome-wide polymorphism rates as compared to smaller commonly used trinucleotide 
sequence (“3-mer”, one flanking nucleotide) context. Previous estimates of de novo mutation rate 
have been limited to either utilizing the 1mer+CpG [17] (no flanking nucleotide except for CpG) or 
3-mer [31, 89] sequence contexts. Therefore, I tested different sequence context models on the 
de novo mutational data from 78 Icelandic family trios. I used a similar likelihood comparison 
framework from my previous work [29] to evaluate competing local sequence context models. I 
calculated the likelihood of the observed de novo variants from a 1-mer+CpG sequence context 
model (Supplementary File 5.3) and found that the 3-mer model based rates (Supplementary 
File 5.4) significantly improved the fit to the data (log likelihood improvement of 4, Table 5.2). I 
then evaluated if additional local nucleotides improved the fit to the data and found that the 7-mer 
context based rates further improved the fit to the data (log likelihood improvement of 271, Table 
5.2) compared to the 3-mer model. Next, I evaluated the performance of 3-mer sequence context 
based de novo mutational rate estimates on mutational data and found that 3-mer model did not 
accurately or as well as the 7-mer model, predict the observed de novo mutations under all the 
substitutions classes or motif (Figure 5.2, 5.3). Therefore, together these analyses indicate for 
the first time that 7-mer context based de novo mutation rates best explain the observed 
distribution of germline de novo mutations found in humans. 
Higher estimate and variability in coding de novo mutation rate  
Protein coding genes unlike the intergenic noncoding regions, are GC rich [159, 160] and 
previous studies have reported a higher overall rate of mutation here relative to the rest of the 
genome [89]. Using my more informative estimates of heptanucleotide sequence context based 
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de novo mutation rates, I also find an overall higher rate of mutation in the protein coding genes. 
However, unlike previous estimates [89, 102] of ~1.5*10-8 mutations per base pair, per generation 
in the coding region, I find a slightly higher mutation rate estimate of 1.72*10-8 (P << 10-6). This 
suggests that the heptanucleotide sequence context based rates capture previously unidentified 
higher mutation rate causing sequence contexts in the protein coding region. Next, I investigate 
the reason behind the higher overall mutation rate estimate from a heptanucleotide sequence 
context model. I find the exonic mutation rate without considering the GC sequence content, 
because protein coding genes have more GC content which has been shown to result in a higher 
rate of mutation [159, 160]. Not surprisingly, I report a lower rate of mutation (1.38*10-8), more 
close to the overall genome-wide rate of mutation of 1.2*10-8 mutations per base pair, per 
generation. This strongly suggests that the heptanucleotide context based coding mutation rate 
estimates are higher because they capture more variability in the GC context in the protein coding 
region. This is also in sync with my previous result [29], where I had demonstrated significant 
variability within heptanucleotide sequence contexts at CpG sites and reported mutation enriching 
motif at TACG sequence context.  
To further validate my findings of higher rate of mutation identified from heptanucleotide 
sequence context based estimates, I compared the observed de novo mutations in an Icelandic 
family trio sequencing dataset with expectations from my model. I find that my results match the 
observed mutations closely, although the expectations from a 1mer+CpG context based coding 
mutation rate model were also within the 95% confidence interval (Observed mutation 46, Mean 
of expectation from heptanucleotide context 45.24, 1mer+CpG context 41.38). Since, very few 
mutations were observed in this trio sequencing dataset to meaningfully compare the 
heptanucleotide estimates of de novo mutation rate with the 1mer+CpG context, I compared the 
fit of our sequence context models on a larger polymorphism dataset from 6,503 individuals of 
European and African ancestry [92]. I limited the analysis to recently originated rare variants 
which have not been subjected to force of selection and mostly shaped due to mutational forces 
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[94] and found that the 7-mer model explained the patterns of these polymorphisms better (Table 
5.3) than any other model. Taken together, these results suggest for the first time an even higher 
rate of mutation in the protein coding region compared to the genome-wide average. 
Previous studies have found variation in the de novo germline mutation rate between genes 
owing to different gene specific sequence contexts and length [31]. Here, I find the overall 
germline mutation rate across all defined transcripts, using the informative heptanucleotide 
sequence context based rates, and also report significant variation (Figure 5.4). Further 
investigating the role of sequence context in determining this variability, I normalized the gene 
specific mutation rate with gene length, and also report significant variability (Figure 5.5), 
suggesting that local sequence context differs between genes and results in significant variation 
in genic mutation rate. Next, I focused on the intra-genic variability in mutation rate. Previous 
studies have reported the first exon in a eukaryotic gene to gene to have a higher GC content 
[161]. Since higher GC content can result in higher mutation rate, so I calculated the de novo 
mutation rate within each exon of my defined transcripts. I found the mutation rate to vary 
significantly across the gene and the normalized rate at first exon to be higher than the remaining 
exons or even the single exon genes (Figure 5.6). This suggests that genes might accrue 
mutations at different rate (both overall, and at specific sub-genic regions) beyond expectation 
due to gene length and cautions against standard normalization approaches by only length or 
simple sequence context models. Moreover, this has direct implication in clinical gene mapping 
studies, because a gene can have a higher burden of mutation compared to another, owing to 
different local sequence context.  
Issues with other approaches for de novo mutation simulation  
The community has successfully demonstrated the role of de novo mutations in several diseases 
including Autism [52, 90], Epilepsy [103] and Congenital Heart disease [53], and have found 
several causal genes with a higher mutation load in affected probands. Virtually all the studies 
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[90, 156], use a Poisson probability distribution to simulate and compare the observed mutation 
burden with expected number of de novo mutations found from a fixed or a trinucleotide 
sequence context based rate estimates. While this is informative, this approach makes several 
assumptions. 
First, the Poisson distribution used to find the expected de novo mutations underestimates the 
variance (although the mean of expected mutations is accurate) when predicting the expected 
mutations after sequencing of haploid chromosome. The correct statistical approach to simulate 
de novo mutations is from a series of independent Bernoulli distribution described in Equation 3 
	 	 …… . . . . . . 	                      (3) 
Where pi is the probability of mutation at nucleotide position i in the sequence. If we sequence n 
haploid chromosomes, then the actual number of mutations is again described as a sum of 
independent Bernoulli random variables (Equation 3, repeated n time for each haploid 
chromosome). The commonly used approach to find expected mutations, simplifies Equation 3 to 
a Poisson distribution in Equation 4. 
	 	  
	 … 	 …                                                          (4) 
where p is the sum of individual mutation probabilities at each nucleotide position in the 
sequence. The mean of Equation 5 and 4 is the same as np. However, the variance in Equation 
3, under the assumption of independence np – np2, while that of a Poisson approximation in 
Equation 4 is still np. This difference of variance is small because individual probability of 
mutation is very small. However, it must be acknowledged when using Poisson approximation to 
simulate and predict mutations at hyper-mutable sites or in species with higher background 
mutation rate.  
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Second, the Poisson distribution approach to find the expected mutations in different substitution 
classes (missense, nonsense, deleterious, synonymous etc.), incorrectly estimates the variance 
in each class (although the mean of expected mutations is accurate). Each nucleotide can mutate 
to another resulting in a different type of change based on the position in the codon frame. For 
example, the nucleotide C in codon CGA can mutate to A, resulting in a synonymous change, 
mutate to G, resulting in a missense change and mutate to T, resulting in a nonsense change. 
However, these mutation probabilities are not independent of each other and we need to model 
the covariance. In Equation 5, I describe a scenario where one is interested in estimating the total 
deleterious mutations over a particular coding region after sequencing n haploid chromosomes. 
The correct statistical approach includes modeling the probability of missense and nonsense 
mutation at each nucleotide position using a Bernoulli distribution. 
	 	 	 	 	 	
	 . . . . 	 	 … 	 	 	 	    (5) 
However, the Poisson approach models the number of deleterious mutation as  
	 	 	  
	 	 	 ⋯ 	                                                                
	 	 	 ⋯ 	                       (6)        
Where pmissense or pnonsense is the sum of missense or nonsense mutation probability at each 
nucleotide in the sequence. The mean of Equation 5 and 6 is the same as n*(pmissense + pnonsense). 
However, the variance in Equation 6 under the Poisson model is n*(pmissense + pnonsense), while in 
Equation 5 we have covariance terms because having a missense or a nonsense mutational 
event at a nucleotide position are not independent of each other. Moreover, the Poisson model 
further does not include the square terms of missense and nonsense probabilities. While the 
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covariance and square terms are small (because of small missense and nonsense probabilities), 
they must be acknowledged when using the Posisson approach. 
Together, these results highlight several approximations in existing approaches for simulation and 
then testing for de novo mutation burden over genomic regions. While the Poisson approach, 
results in accurate estimate of the mean number of expected mutations, the variance can be off 
when the background rate of mutation is high. This can have implications in mutation burden tests 
because simulations from Poisson distribution are used to compare the observed burden with 
expected, and infer significance. While existing studies have mostly focused on a few genes after 
sequencing of some individuals, studies of future with complex analysis on a large dataset, in 
hyper-mutable regions or non-human species with higher mutation rate, can be compromised 
with the Poisson distribution approach.  
Toolkit for simulating, distributing and interpreting de novo mutations 
My central objective here is to develop a framework to find the expected number of mutations 
over any region of the genome based on a background model of mutation rate, which can then be 
used for understanding the process of mutagenesis under different conditions [162–164] or 
finding the causal gene or locus from disease sequencing studies [6, 90, 97]. To achieve this 
objective, I need (a) an accurate model of variation in background mutation rate and (b) an 
algorithm to simulate and distribute mutations over any region of the genome. I have previously 
demonstrated that a heptanucleotide sequence context model, accurately captures the variability 
in the genome-wide rate of mutation. Therefore, here I use the informative de novo mutation rate 
estimates from the 7-mer sequence context model in my framework. I perform my analysis over 
any genomic region, which can be specified via genomic coordinates or using ENSEMBL 
transcript ids. The final output, includes the expected count of mutations over the genomic region, 
further sub-classified into substitution classes (transition or transversion, if genomic region 
includes coding territory then synonymous, missense, nonsense, splice, individual amino acid 
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annotations). I also output the genomic regions with simulated mutations at different positions, 
which the user can then analyze based on their specifications. 
I first develop an algorithm to simulate de novo mutations of any genomic region of interest. This 
is geared towards a user interested in finding the occurrence of de novo mutations over a region, 
after sequencing n individuals (or 2n haploid chromosomes). A common question asked in most 
family trio disease sequencing studies, is if the observed count of mutations in a gene or a 
pathway is unusually higher or lower than expected under a background model of mutation rate. 
An unusual observation will suggest a protective or causal role of the gene or pathway in disease 
pathogenesis. My algorithm extends the multinomial probability distribution framework, where I 
simulate mutations at all occurrences of heptanucleotide sequence contexts in a region using the 
heptanucleotide de novo mutation rate estimates. Over multiple simulations and total haploid 
chromosomes (both given as input by the user) sequenced, I use my algorithm to decide where 
mutations occur in the genomic region, in each simulation. Finally, I output the 95% confidence 
interval of the total and substitution class specific mutation count from the simulated data.  
Next, I developed an algorithm to distribute de novo mutations across any genomic region, in 
order to generate an expected count of mutations (with variance) at all positions in the region. 
This is geared towards a user interested in comparing the mutations observed in a disease 
ascertained sample, with an expected distribution from a background model of mutation rate. A 
common question asked after causal gene discovery is, whether mutations in a disease 
ascertained sample are enriched at certain sub-genic sequences. An enrichment of mutations at 
a particular genic locus in a disease ascertained sample can suggest higher pathogenicity, and 
vice versa for mutations observed in a sample ascertained against disease status. Here too, I 
extend my multinomial probability distribution framework to distribute mutations over multiple 
simulations (both given as input by the user) on a particular genomic region. I find the probability 
of mutation at each position in the genomic region, and then use a multinomial distribution with 
the calculated probabilities to distribute the mutations. Finally, I output the 95% confidence 
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interval of substitution class specific mutation count from the multiple simulations used to 
distribute mutations over the genomic region. 
Together, these functionalities of simulation and distribution provide a systematic framework to 
find the expected spectrum of mutations over a genomic region, based on the background 
mutation rate. While previous approaches mostly focused on the simulation aspect [156], using 
the less informative trinucleotide sequence context based mutation estimates, my approach 
including the novel distribution algorithm provides a generalized framework for interpretation of de 
novo mutations in clinical studies. Moreover, my approach also improves the resolution by finding 
expected mutations over any genomic region (gene set or sub-genic loci) and for any substitution 
class. I implement these functionalities as a part of a toolkit called SimDenovo, which can serve 
as a useful resource for the community interested in analyzing and interpreting disease 
sequencing mutational data.
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CHAPTER 6: Discussion and Future work 
Mutation is the most important force that has shaped our genomes since we evolved from single 
cell species [1]. It generates genetic variation on which evolution acts [2], causes variation 
between individuals of same [3] and different species [4], results in cell to cell heterogeneity [5] 
and is responsible for genetic disorders; inherited [6] or somatic [7] like cancer. Hence, 
understanding how mutations originate across the genome is fundamental to our understanding 
of life. Previous work over the last century, has successfully discovered and described the 
process of mutation [3, 8] in single celled organisms to complex eukaryotic species like Homo 
sapiens. An important finding across the entire evolutionary tree has been that the rate of 
mutation varies significantly across genomes  [28, 30], and it has critical implications in 
understanding evolution, disease and mutagenesis biology. 
Previous studies have shown that local sequence context correlates with, and in specific cases, 
directly modifies the rate of mutation [30]. An exquisite example is the CpG sequence context, 
where spontaneous deamination of methylated cytosine elevates the cytosine to thymine 
mutation rate by ~15-fold higher relative to the genome-wide background [28, 104]. The 
community has incorporated local sequence context around the polymorphic site, i.e. 1 base pair 
on either 5’ or 3’ end for a total of 3 nucleotides or trinucleotide sequence context, to model and 
understand the variability in mutation rate [30–32, 89]. However, the role of larger sequence 
context in explaining the variation in mutation rate has not been systematically evaluated. 
Therefore, in this thesis, (a) I proposed a statistical model for the probability of nucleotide 
substitution in the genome based on windows of nucleotide sequence context, (b) using this 
model, proposed a framework to statistically test competing windows of sequence context, and 
concluded that a broad (heptanucleotide) context best explained population level and de novo 
mutational data, (c) utilized inferences about the rates generated from my predicted sequence 
context model to ask several questions, ranging from identification of causal genes, testing 
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specific disease hypotheses, or sub-gene burden of de novo mutations, as applied to multiple 
disease sequencing datasets. 
In chapter 2, I evaluated different sequence context models found that a larger heptanucleotide 
sequence context model best explained patterns of nucleotide substitution observed in the human 
genome. I demonstrate that the commonly used context that includes one nucleotide flanking a 
polymorphic site does not fully capture the complete spectrum of where, what type, and how 
frequently nucleotides are expected to change. I also find novel variability in substitution 
probabilities at CpG sites, and found certain heptanucleotide CpG contexts to have a much 
higher or lower rate of substitution. Moreover, I also show that this previously unidentified 
variability at CpG sites cannot be fully explained by differential methylation intensity patterns. 
Furthermore, I identify novel mutation promoting motifs at TACG and ApT and CAAT sites. 
Finally, I demonstrate that nucleotide substitution probabilities capture features of germline 
mutation rate as they are consistent and correlated (a) across the frequency spectrum of variants, 
(b) between high and low recombination regions, (c) with human primate divergence and (d) with 
real de novo mutational counts.  
One question in the field has been how much sequence context can explain patterns of 
nucleotide substitution in genomes [165]. My results suggest that a substantial fraction can be 
robustly predicted by sequence context alone, although specific substitution classes may require 
more features than just sequence context. I also acknowledge that context models beyond three 
flanking nucleotides were not considered. The regression approach that I presented does suggest 
that the 7-mer models could be refined, perhaps allowing broader context to be considered. 
Furthermore, evolutionary genetics studies require an estimate of mutation rate for accurately 
dating divergence events [166]. Since, most of these studies incorporate a simplistic model of 
mutation rate variation at CpG and non CpG sites, they can vastly benefit from a more informative 
model of mutation rate variation at the level of sequence context.  
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While I did not apply my model to other species, the strong correlation with divergence suggests 
that the features of mutation are potentially conserved across primates. The same framework can 
be applied to population level sequencing datasets in other species [167, 168] to discover 
features of mutation (if any) specific to them. Moreover, comparative genomics applications to 
identify non-neutrally evolving regions, genome alignments, or tree reconstruction [157], would 
benefit from my accurate model of nucleotide substitution.  
Here, by using population level data with millions of SNPs rather than smaller de novo mutations 
dataset, I was able to improve the resolution of substitution models and model variability in 
substitution/mutation rates. Because SNPs in intergenic, noncoding regions are mostly shaped 
due to forces of mutation (and population demographic forces), this strategy can be applied on 
larger datasets (e.g., dataset from sequencing of 100K individuals from UK) to further improve the 
human substitution probability estimates and learn about features of germline mutation. I also 
acknowledge that a number of features remain to be formally evaluated in the genome [8], for 
example, recombination in the coding genome [169] or replication timing [170]. My framework has 
the flexibility to model the complexity found in any sequences that contain features hypothesized 
to be important. 
With an appropriate background model for nucleotide substitution, novel statistics for clinical re-
sequencing studies can also be envisioned, based on the occurrence of discovered variation. 
Such approaches may complement statistics that assay allele frequency differences between 
cases and controls at one or more polymorphic sites. While the underlying mechanisms that 
determine how nucleotide sequences change over time remain to be addressed, I posit that 
features identified from my model provide important clues in elucidating these fundamental 
principles.  
In chapter 3, I extended my substitution probability framework to the coding region and 
characterized average selective pressures operating in the coding genome at a finer level of 
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detail. I first demonstrate that a heptanucleotide sequence context model that incorporates both 
(a) the mutational forces using substitution rates in the noncoding region, and (b) selective forces 
through the codon position effects in the coding region, best explain patterns of coding 
substitutions compared to a commonly used trinucleotide sequence context model. My model 
also indicates substantial variability across all amino acid replacement classes, and, in some 
cases, synonymous substitutions that were less prone to change than missense or even 
nonsense substitutions. Furthermore, I modeled the average selective force acting on the coding 
genome at each sequence context stratified by codon position, and developed several clinical 
utilities of interest consistent with purifying selection and disease hypothesis [47]. First, I show 
that nonsense and missense variants in 1KG dataset of population controls have a higher 
selective constraint on them compared to synonymous polymorphisms, but less than on the 
putative disease causing variants in the HGMD dataset. Second, I develop a statistic to quantify 
the functional intolerance or selective constraint at the level of a gene. Referred to in the 
community as a “gene score” [31, 171], I demonstrate that such measures have the best 
performance to grade intolerance when incorporating heptanucleotide sequence context. I show 
that genes associated with essentiality in humans or are ubiquitously expressed in different 
tissues, and associated with several neuropsychiatric diseases have more intolerant gene scores, 
while those associated with immune function are more tolerant. Third, I further improve the 
resolution and find amino acid scores that measure the intolerance of an amino acid to functional 
changes and find several examples of localized intolerance at the level of amino acid but 
tolerance at overall genic level. Finally, I apply these scores to a de novo disease sequencing 
dataset of Autism probands, and show that previously discovered genes and variants in this set of 
genes have more intolerance and further suggest the role of some novel genes in Autism.  
Here, I modeled the selective constraint acting in the coding genome at a fine scale, by 
comparing the polymorphisms in the coding region with that in the intergenic noncoding region. 
Assuming that noncoding regions I curated are shaped mostly due to mutational forces 
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(attempting to minimize selective pressures), I utilized the ratio of the two substitution probabilities 
to find the selective force at each sequence context in the coding region to quantify the extent of 
purifying selection of different types of mutation. In future, with large exome sequencing datasets 
in the coding region, the coding substitution probability estimates can be further improved to 
obtain more accurate estimates of selection. Moreover, amino acid and gene scores can be 
further improved as in the current dataset of 1KG controls, some genes or amino acids had very 
few substitutions to train our model on. Furthermore, with larger datasets the resolution of 
intolerance scores can be further improved and can also be developed for other annotations like 
exon level or different sub-genic locus.  
I also find significant variation in substitution patterns in the coding region, and found some amino 
acid substitutions (even nonsense changes like from Arginine to Stop) to occur more than others 
(synonymous or missense changes). Therefore, more powerful rare variant burden tests can also 
be envisioned which incorporate the background probability of occurrence of a rare variant in the 
sequencing dataset. 
While the community has been extensively using intolerance scores for prioritizing genes 
discovered from clinical sequencing datasets [31, 125], my intolerance scores can further benefit 
such studies. Moreover, my unique amino acid scores, which measure intolerance at the level of 
amino acid can be further used to prioritize both genes and variants discovered from disease 
sequencing datasets for follow up. Finally, the studies that infer the presence and strength of 
selection on genes might further benefit by incorporating my intolerance scores. 
In chapter 4, I developed a generalized approach, which models the variability in mutational 
probabilities at sequence context level and finds enrichment of de novo mutations at sub-genic 
loci from sequencing datasets. Enrichment of mutations at a locus in disease ascertained 
samples can suggests localized pathogenicity within a gene, and can be used to further elucidate 
disease mechanisms. I applied the generalized approach to a large dataset of de novo germline 
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mutations in bilateral RB patients without a previous family history of disease. First, I show that 
the frequency of nonsense mutations at CpG sites is compatible with the background model for 
the known, elevated rate of mutation at these sites. A parsimonious interpretation of this result is 
simply that nonsense mutations at CpG sites in RB1 are, in fact, not preferentially RB pathogenic. 
Instead, the abundance of Arginine to Stop mutations can simply be explained by (i) 
ascertainment of RB affected probands, (ii) that LoF at RB1 causes RB, and (iii) the mutability of 
this sequence context [14, 33]. Second, I identified heterogeneity in the frequency of essential 
donor splice-site mutations across RB1. In particular, I found a depletion of essential donor splice 
site mutations in intron 5, explainable by the fact that exon 5 skipping retains the coding frame (at 
the loss of a 13 amino acid deletion) and thus may only be weakly penetrant. I also found more 
mutations at essential donor splice-sites of introns 6 and 12 than predicted by my model, which 
result in frame-shift and putative loss of function (LoF) mutations. Here, I note that essential 
donor splice-sites in other introns also result in frame-shift and putative LoF. Thus, a mechanistic 
explanation as to why exon 6 and 12 skipping and consequent frame-shift LoF would be 
specifically ascertained in our probands remains elusive. Nonetheless, statistical quantification of 
this specific enrichment, to my knowledge, has not been previously reported. Finally, I quantified 
the excess of missense mutations in Exon 20, localized specifically to Arg661Trp. While I noted 
the recurrence of five mutations to this specific codon, as well as and enrichment in another 
LOVD dataset, I was not able to distinguish the relative frequency of this mutation from the rate of 
nonsense owing to the small number of events in the dataset. Previous reports in the literature 
gives some indication that this mutation is indeed low penetrance [27–29], and my results are 
consistent with these reports. 
A major challenge in de novo mutational studies of rare and complex disease is to not only 
identify new pathogenic mutations, but also to statistically quantitate the enrichment of specific 
types of pathogenic mutations within a gene, in order to improve the understanding of gene-
specific disease etiology. Here, my motivation was based on the need to statistically evaluate 
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specific hypothesis about the relative abundance – and inference about pathogenicity – of de 
novo mutations identified in probands selected for bilateral RB. This study of sporadic RB cases 
identified under a research protocol represents the single largest dataset of de novo mutations in 
the RB1 gene reported to date. Thus, it removes many uncertainties associated with other data 
sets where there are many sources of non-homogeneity including sample ascertainment and 
methods used for mutation detection. Moreover, the significance of identifying de novo mutations 
for affected probands includes not only clinical management decisions, but also risk of a second 
cancer in the future as well as having additional, affected offspring. Thus, investigating the 
pathogenicity of de novo mutations in this study is both mechanistically and clinically relevant. 
However, this analysis using my generalized framework would vastly benefit from a larger dataset 
of mutations and can allow for testing and discovery of several novel disease hypotheses.  
Moreover, with sufficient data and a specific probabilistic model, it is conceivable to utilize my 
approach to derive posterior distributions for penetrance for different classes of mutations. Such 
may be the focus of future work. I focused here exclusively on the analysis of RB, owing to the 
systematic extent that this disease has been previously studied, the preponderance of existing 
data sets, and minimal genetic heterogeneity for the condition. Despite this, my efforts helped to 
clarify existing hypotheses in the field around mutational mechanisms for the gene and point to 
new areas to study for this already well-studied disease. That said, my framework could be 
readily applied to other Mendelian diseases or complex disorders. While each disease endpoint 
will have particular biological mechanisms to elucidate, the model and approach I present should 
provide a statistical framework to identify sequence-based features that point to unknown 
mechanisms underlying human disease. 
In chapter 5, I generated accurate and informative estimates of de novo mutation rate for 
different sequence context models. I showed that estimates of de novo mutation rate at 
heptanucleotide sequence contexts are more informative than the commonly used trinucleotide 
estimates for contexts on an external dataset of de novo mutations. Moreover, the 
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heptanucleotide estimates accurately predict the observed pattern of mutations. I also find a 
higher yet accurate estimate of the mutation rate in the coding region suggesting the presence of 
more mutable GC rich contexts, which is captured by the heptanucleotide sequence context. I 
also demonstrate significant inter and intra-genic variability in mutation rate across the genes, 
suggesting the need and importance of a mutation rate framework which can incorporate this 
variability and interpret mutations in a disease sequencing study. I show that the commonly used 
approach for simulating mutations is informative, but uses many assumptions which must be 
acknowledged in more complex studies. Finally, I develop a generalized framework which can (a) 
find expected mutations over any genomic region after sequencing n individuals and (b) distribute 
N mutations and find expected at any context under a background model for mutation rate. 
Together these functionalities can be used to simulate, distribute and interpret de novo mutations 
in different diseases.  
Here, I was motivated by the need of the community to have an accurate estimate of de novo 
germline mutation rate which can then be used in several applications from modeling of 
evolutionary processes [15] to finding the causal gene from de novo sequencing studies for 
different diseases [52, 90]. Since, I had earlier shown that the heptanucleotide sequence context 
captures feature of germline mutation rate, so now I find actual estimates at each context, such 
that the overall de novo mutation rate is fixed at 1.2*10-8 mutations per nucleotide, per 
generation. In future, if the overall mutation rate gets revised to a higher or lower number, or if we 
want to find it in different species, we can correspondingly scale the mutation rate estimates at 
each sequence context. I also validate my mutation rate estimates on an external dataset of 
~4748 mutations, but it would be interesting to exhaustively compare the accuracy on larger 
datasets.  
I also find a higher mutation rate estimate in the protein coding region. Protein coding genes have 
a higher GC content, which are more mutable sequences and hence previous studies had also 
reported a higher rate of mutation in the coding region [89, 90]. However, I find an even higher 
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mutation rate, suggesting the presence of some more mutable contexts. Further improving the 
resolution of these mutable contexts can help clarify evolutionary processes and mechanism that 
resulted in more mutable coding regions. Moreover, it would be interesting to characterize the 
variability in gene specific mutation rate (after normalizing by length), and to understand the 
complex relationship between higher mutation rate at a gene and overall fitness [172]. I also 
demonstrate that the first exon has a higher mutation rate than the rest of the gene body, but the 
evolutionary processes shaping this phenomenon are not clear. Since higher mutation rate can 
result in more deleterious mutations, which have a detrimental effect on fitness [173], future work 
could focus on unraveling the beneficial effects to organismal fitness from having a higher 
localized mutation rate within a gene.  
Finally, using my mutation rate framework for simulation and distribution of mutations, powerful 
tests can be envisioned that measure the burden of mutation rate in several clinical studies. 
Current approaches [90, 156, 174] only compare the burden of mutations in cases and controls. 
While this is informative, it does not capture other features which can add more power to the 
testing strategy. For example, using a fine scale model of mutation rate variability and my unique 
distribution function, one can develop new test that also compares the deleterious to non-
deleterious mutation rate burden in cases and controls. This additional feature, combined with 
other features of localized or specific higher burden of mutation rate can be used to compare the 
mutational burden and test for specific hypotheses.   
In conclusion, the general theme of my thesis research has been to characterize and model the 
variability in human mutation rate. Mutation rare is a fundamental quotient in human genetics, and 
its accurately modeling can be used to answer innumerable questions ranging from basic biology 
to translational therapeutic applications. The work presented in my dissertation has laid a solid 
foundation for study of variation in mutation rate, and provides a systematic framework for 
interpretation of clinical sequencing data to find causal genes or test for specific disease 
mechanisms. Studies of future can build on my mutation rate framework to advance our 
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knowledge of human origins and evolutionary processes, and also to summarize and interpret the 
vast disease sequencing datasets for all genetic diseases.    
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TABLES 
Table 2.1 Comparison between substitution probabilities from HapMap and1KG data. R2 and 
correlation between the substitution probabilities estimated using HapMap and 1000 Genomes 
variant data from the intergenic non-coding genome, for different sequence context models (3-
mer model with randomized sequence context beyond adjacent nucleotides, 7-mer model). Also 
shown is the comparison specific for CpG and nonCpG sequence contexts. 
Sequence 
Context type 
R^2 of 7-
mer 
model 
Correlation 
with 7-mer 
model 
R^2 of 3-mer model with 
randomized sequence 
context beyond adjacent 
nucleotides 
Correlation of 3-mer 
model with 
randomized sequence 
context beyond 
adjacent nucleotides 
All 0.91 0.95 0.84 0.91 
CpG only 
contexts 
0.88 0.94 0.78 0.88 
non CpG 
contexts 
0.75 0.87 0.6 0.77 
 
Table 2.2 Substitution probabilities for different populations and chromosomes. Average 
nucleotide substitution probabilities for different population groups (African, European, and Asian) 
on different types of regions (coding versus intergenic non-coding) and on different chromosomes 
(All autosomal versus X chromosome). 
 African Substitution 
Probability 
Asian Substitution 
Probability 
European Substitution 
Probability 
All IGR 0.009454398 0.005240961 0.006142976 
Autosomal IGR 0.00971703 0.00541551 0.006339118 
X chromosome 
IGR 
0.006122926 0.00302682 0.003654918 
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Autosomal 
Coding 
0.007195663 0.004923134 0.005478647 
 
Table 2.3 Variance in a class explained by different models. Summary of Summary and 
performance of forward regression model for feature selection using the 7-mer context in the 
intergenic non-coding genome. % Substitutions represents the percentage of substitutions for that 
class observed in the genome. # Parameters represents the number of features selected in the 
best 7-mer model. Model R2 (7-mer) reflects prediction accuracy in the test dataset alone (not 
used for model training) with the best model using heptanucleotide sequence context features. 
Model R2 (3-mer) denotes the prediction accuracy with only trinucleotide sequence context 
features.   
Substitution Class # Contexts % Substitutions # Parameters Model R2 
(7-mer) 
Model R2 (3-
mer) 
Outside CpG Dinucleotide Context 
A-to-C 4096 7.3 266 56.5 11.2 
A-to-G 4096 28.2 366 91.5 40.9 
A-to-T 4096 7.1 197 58.7 37.4 
C-to-A 3072 8.5 282 83.5 30.0 
C-to-G 3072 7.5 268 81.0 17.1 
C-to-T 3072 24.4 254 86.8 37.6 
Within CpG Dinucleotide Context 
C to A 1024 1.0 26 58.3 19.0 
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C to G 1024 0.8 95 48.7 9.5 
C to T 1024 15.2 96 93.1 44.4 
 
Table 2.4 Sequence motifs identified from substitution probabilities from 1KG data. Enrichment of 
motifs identified in posterior nucleotide substitution probabilities for the 7-mer sequence context 
models inferred from intergenic non-coding genome. CpG+ indicates the distribution of sequence 
contexts which include a CpG site (4th position polymorphic site is C, 5th position fixed as G). 
Enrichment P-value is based on the enrichment of the motif in the 1% tail of the given substitution 
class: “Higher” implies enrichment in the upper 1% tail of the sequence context probability 
distribution, “Lower” implies enrichment in the lower 1% tail. Odds ratio and [95% CI] denotes the 
odds ratio (and 95% confidence interval) of enrichment of motif in the upper or lower 1% tail of 
the sequence context probability distribution. Fold change in substitution rate denotes the fold 
increase or decrease in substitution rates for the motif relative to its substitution class. 
Motif Substitution 
Class 
Effect on 
Substitution 
Probability 
Enrichment 
P-value 
Odds ratio and 
[95% CI] 
Fold change in 
substitution 
rate 
NNNCGNN C-to-T Higher 2 x 10-26 134.4 
[18.4 - 977.4] 
13.9 
C-to-G Higher 1 x 10-13 12.8 
[5.9 - 27.7] 
2.4 
C-to-A Higher 9 x 10-22 60.8 
[14.6 - 252.1] 
2.7 
88 
 
N[A/C/G][C/G/T]CG
CG 
C-to-T 
(CpG+) 
Lower 7 x 10-16 366.3 
[45.6 - 2939.5] 
1.5 
Poly T and Poly A 
combination 
(AAAATTT, 
TTTAAAA) 
A-to-T Higher 9 x 10-5 304.2 
[31.0 - 2987.6] 
12.7 
Quad A (AAAANNN, 
NAAAANN, 
NNAAAAN,NNNAA
AA) 
A-to-G Lower 5 x 10-10 10.2 
[7.3 - 14.1] 
1.9 
NTACG[C/G][A/C/G] C-to-T 
(CpG+) 
Higher 1 x 10-10 102.5 
[27.4 - 383.2] 
1.7 
NNTACGN A-to-C Lower 3 x 10-4 9.4 
[3.6 - 24.8] 
1.5 
NNNATNN A-to-T Higher 2 x 10-17 22.3 
[8.7 - 57.1] 
1.6 
A-to-G Higher 1 x 10-25 131.2 
[18.0 - 954.2] 
2.0 
[C/T]CAAT[C/G/T]N A-to-G Higher 8 x 10-53 5966 
[2091 - 17021] 
5.1 
 
Table 2.5 Sequence motifs identified from substitution probabilities from HapMap data. 
Enrichment of motifs identified in nucleotide substitution probabilities inferred from HapMap 
variant data in the intergenic non-coding genome. CpG+ indicates the distribution of sequence 
contexts which include a CpG site (4th position polymorphic site is C, 5th position fixed as G). 
Enrichment P-value is based on the enrichment of the motif in the 1% tail of the given substitution 
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class: “Higher” implies enrichment in the upper 1% tail of the sequence context probability 
distribution, “Lower” implies enrichment in the lower 1% tail. Odds ratio and [95% CI] denotes the 
odds ratio (and 95% confidence interval) of enrichment of motif in the upper or lower 1% tail of 
the sequence context probability distribution. Fold change in substitution rate denotes the fold 
increase or decrease in substitution rates for the motif relative to its substitution class. 
Motif Substitution 
Class 
Effect on 
Substitution 
Probability 
Enrichment 
P-value 
Odd’s ratio 
and [95% CI] 
Fold 
difference in 
substitution 
rate 
NNNCGNN C-to-T Higher 2 x 10-25 134.4 [18.5 - 
977.4] 
10.1 
C-to-G Higher 2 x 10-26 131.4 [18.1 - 
956.2] 
2.8 
C-to-A Higher 1 x 10-25 128.1 [17.6 - 
933.0] 
3 
N[A/C/G][C/G/T]
CGCG 
C-to-T 
(CpG+) 
Lower 2 x 10-16 43.6 [12.2 - 
155.3] 
4.4 
Poly T and Poly 
A combination 
(AAAATTT, 
TTTAAAA) 
A-to-T Higher 9 x 10-5 304.2 [31.0 - 
2987.6] 
7.7 
Quad A 
(AAAANNN, 
NAAAANN, 
NNAAAAN,NNN
AAAA) 
A-to-G Lower 1 x 10-2 3.1 [2.1 - 4.8] 2.1 
NTACG[C/G][A/C
/G] 
C-to-T 
(CpG+) 
Higher 2 x 10-6 43.6 [12.2 - 
155.3] 
2.3 
NNTACGN A-to-C NA Not 
Significant 
NA 1.1 
NNNATNN A-to-T NA Not 
Significant 
NA 1.5 
A-to-G Higher 2 x 10-21 41.5 [12.8 - 
134.5] 
1.8 
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[C/T]CAAT[C/G/T
]N 
A-to-G Higher 8 x 10-53 5966 [2091 - 
17021] 
4.4 
 
Table 2.6 Substitution probabilities and human primate divergence. R2 and correlation between 
the substitution probabilities in intergenic non-coding genome and human primate divergence at a 
context, for different sequence models (3-mer model with randomized sequence context beyond 
adjacent nucleotides, 7-mer model). Also shown is the comparison specific for CpG and nonCpG 
sequence contexts. 
 CpG Contexts  
Correlation 
with 7-mer 
model 
R^2 of 3-mer model with randomized 
sequence context beyond adjacent 
nucleotides 
Correlation of 3-mer model with 
randomized sequence context beyond 
adjacent nucleotides 
0.99 0.92 0.96 
0.92 0.44 0.67 
0.69 0.16 0.41 
 Non CpG Contexts  
Correlation 
with 7-mer 
model 
R^2 of 3-mer model with randomized 
sequence context beyond adjacent 
nucleotides 
Correlation of 3-mer model with 
randomized sequence context beyond 
adjacent nucleotides 
0.98 0.93 0.96 
0.91 0.41 0.64 
0.72 0.22 0.47 
 
Table 2.7 De novo mutations at identified motifs. Expected (95% CI) and observed de novo 
mutations for each class of change calculated on high quality pedigree sequencing data from 78 
trios[16]. If number of observed mutations fall in the expected confidence interval, then I denote it 
“As expected” otherwise as “Higher than expected”. 
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Mutation Class 95% CI of expected 
de novo mutations 
Observed de 
novo mutations 
Comparison of observed 
mutations with expected 
mutations 
C-to-T [1804, 1974] 1,952 As expected 
C-to-T at CG 
sites 
[67, 104] 816 Higher than expected 
C-to-T at TACG 
sites 
[1, 8] 54 Higher than expected 
A-to-G [1245, 1388] 1,279 As expected 
A-to-G at AT 
sites 
[307, 380] 588 Higher than expected 
A-to-G at CAAT 
sites 
[11, 28] 72 Higher than expected 
A-to-G at CTAT 
sites 
[9, 24] 67 Higher than expected 
A-to-T [303, 375] 316 As expected 
A-to-T at AT 
sites 
[70, 107] 120 Higher than expected 
 
Table 3.1 Comparison of different substitution probability models in the coding region. Natural 
logarithm of the approximate Bayes Factor comparing the posterior likelihoods of the 3-mer 
context model with and without accounting for codon context, and my proposed 7-mer context 
model which does include codon context on multiple data sets. I present data from the African 
and European groups (1KG) and an analysis of the EVS dataset (individuals of European 
ancestry) after filtering out variants with minor allele frequencies less than 0.03%. 
Dataset Population Approximate ln(Bayes 
Factor) comparing the 
basic 3-mer model with 
the coding 7-mer model 
Approximate ln(Bayes 
Factor) comparing the basic 
3-mer model with codon 
offset with the coding 7-mer 
model 
1000 Genomes African 599417 529074 
1000 Genomes European 611063 546810 
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EVS European 568402 504888 
       
Model Number of 
Parameters 
   
Basic 3-mer model 192    
Basic 3-mer model 
with codon offset 
576    
7-mer coding 
model 
73728    
 
Table 3.2 Comparison of gene tolerance scores from different approaches. Prediction accuracy 
of gene tolerance scores to classify membership in various gene sets analyzed in this study. Area 
under the curve (AUC) calculations for gene scores of and my 7-mer codon context gene scores. 
Gene Classes AUC of 
Petrovaski 
AUC of 
Samocha 
AUC of Aggarwala 
Essential 0.66 0.55 0.68 
Ubiquitous 0.59 0.53 0.7 
Immune 0.53 0.51 0.54 
Omim Denovo 0.66 0.58 0.67 
Omim Dominant 0.65 0.54 0.65 
Omim 
Haploinsufficient 
0.73 0.6 0.73 
Olfactory 0.81 0.52 0.83 
Keratin 0.69 0.51 0.7 
Autism 0.83 0.67 0.82 
Intellectual Disability 0.82 0.73 0.89 
Developmental 
Disorder 
0.81 0.7 0.8 
Epilepsy 0.92 0.81 0.91 
All Disease (Autism, 
Epilepsy, Intellectual 
Disability and 
Developmental 
Disorder) 
0.82 0.7 0.86 
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Table 4.1 Variant counts in different categories from RB and ExAC datasets. Counts of de novo 
mutations in RB1 ascertained from RB patients, and singleton variants identified in ExAC from 
(non-Finnish) Europeans for various subtypes. 
Variant Type RB de novo mutations ExAC singletons 
Overall 268 149 
Nonsense 150 1 
Missense 27 56 
Essential Splice 86 1 
Intronic 5 91 
 
Table 4.2 Enrichment of nonsense mutations at different amino acids. Comparison of the 
observed number of nonsense de novo mutations to the simulated frequency predicted by my 
sequence context model. Data shown for all amino acids which can change to a stop codon as 
well as Arginine codon partitioned by CpG context. CI: Confidence Interval. 
Amino Acid 99% CI of simulation Observed variants Empirical P 
Lysine [0, 11] 3 0.336 
Serine [2, 15] 6  0.404 
Leucine [1, 13] 5 0.454 
Glutamine [5, 23] 15 0.385 
Tryptophan [1, 13] 3 0.126 
Arginine [73, 104] 95 0.188 
Glutamic [4, 20] 14 0.243 
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Glycine [0, 6] 3 0.211 
Cysteine [0, 7] 1 0.399 
Tyrosine [2, 16] 5 0.143 
 
Arginine Codon 99% CI of simulation Observed variants Empirical P 
CGA [73, 104] 93 0.237 
AGA [0, 4] 2 0.209 
 
Table 4.3 Enrichment of nonsense mutations at different exons in an external dataset. 
Comparison of observed mutations and the simulated frequency of nonsense changes per exon, 
to find differential pathogenicity within nonsense mutations. Analysis was performed on data from 
Onadim and Houdayer groups to further validate my results on an external dataset. 
Exon 99%CI of Simulation Observed variants P value 
2 [0, 8] 3 0.536 
3 [0, 7] 1 0.328 
4 [0, 5] 2 0.392 
5 [0, 3] 2 0.187 
6 [0, 4] 0 0.365 
7 [0, 6] 1 0.379 
8 [3, 17] 8 0.374 
9 [0, 3] 0 0.694 
10 [2, 15] 7 0.556 
11 [1, 13] 12 0.015 
12 [0, 7] 1 0.264 
13 [0, 7] 1 0.319 
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14 [4, 18] 13 0.233 
15 [1, 13] 9 0.17 
16 [0, 4] 1 0.572 
17 [5, 21] 16 0.149 
18 [1, 13] 4 0.264 
19 [0, 6] 3 0.365 
20 [0, 8] 3 0.508 
21 [0, 5] 0 0.275 
22 [0, 6] 5 0.054 
23 [1, 12] 8 0.21 
24 [0, 4] 0 0.474 
25 [0, 6] 0 0.241 
26 [0, 3] 0 0.452 
27 [3, 18] 0 0 
 
Table 4.4 Enrichment of nonsense mutations at different AA’s in an external dataset. Comparison 
of observed mutations and the simulated frequency of nonsense changes to find differential 
pathogenicity within nonsense mutations. Data shown for all amino acids and two arginine 
codons (99% CI) which can change to a stop codon. Analysis was performed on data from 
Onadim and Houdayer groups to further validate my results on an external dataset. 
Amino Acid 99% CI of 
simulation 
Observed 
variants 
P value 
Lysine [0, 8] 1 0.179 
Serine [1, 12] 4 0.491 
Leucine [0, 10] 2 0.246 
Glutamine [3, 17] 9 0.554 
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Tryptophan [0, 10] 3 0.424 
Arginine [48, 72] 66 0.107 
Glutamic [2, 15] 9 0.318 
Glycine [0, 4] 0 0.343 
Cysteine [0, 5] 1 0.6 
Tyrosine [1, 12] 5 0.509 
    
Arginine 
Codon 
99% CI of 
simulation 
Observed 
variants 
P value 
CGA [47, 71] 63 0.241 
AGA [0, 3] 3 0.016 
 
Table 4.5 Unusual distribution of essential donor splice mutations at different exons. Comparison 
of the observed number of essential donor splice-site de novo mutations at exons 6, 12, and 5 to 
the simulated frequency predicted by my sequence context model. “LOVD count” denotes the 
point variants observed at this site in the LOVD dataset. CI: Confidence Interval. 
Location 99% CI of simulation Observed variants Empirical P LOVD count 
Exon 6 [0, 2] 3 3 x 10-4 40 
Exon 6 [0, 4] 9 < 10-6 40 
Exon 12 [0, 10] 13 4 x 10-4  67 
Exon 5 [1, 12] 0 3 x 10-3 2 
 
Table 4.6 Polyphen prediction on different missense variants. Polyphen predictions on the de 
novo germline missense mutations or some potential variants near codon 661 in RB1 gene. 
“Polyphen2_format” is the variant format accepted by the Polyphen2 tool. “Polyphen_prediction” 
is the result of Polyphen2 on the missense variant.   
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All de novo germline missense mutations  
gDNA 
position 
Reference 
allele 
Alternate 
allele 
Polyphen2 format Polyphen2 prediction 
39554 G A chr13:48916843 G/A benign 
77027 A G chr13:48954327 A/G probably damaging 
156836 C A chr13:49033967 C/A probably damaging 
76454 T G chr13:48953754 T/G probably damaging 
78278 C T chr13:48955578 C/T probably damaging 
156717 T C chr13:49033848 T/C probably damaging 
156713 C T chr13:49033844 C/T probably damaging 
156713 C T chr13:49033844 C/T probably damaging 
156713 C T chr13:49033844 C/T probably damaging 
156713 C T chr13:49033844 C/T probably damaging 
156713 C T chr13:49033844 C/T probably damaging 
73868 A T chr13:48951169 A/T probably damaging 
59789 A G chr13:48937089 A/G probably damaging 
160740 G A chr13:49037877 G/A probably damaging 
65437 G T chr13:48942736 G/T probably damaging 
61745 T A chr13:48939045 T/A benign 
150002 C T chr13:49027133 C/T probably damaging 
39561 G A chr13:48916850 G/A benign 
39561 G A chr13:48916850 G/A benign 
73828 G A chr13:48951129 G/A probably damaging 
156698 C T chr13:49033829 C/T probably damaging 
56923 T A chr13:48934223 T/A probably damaging 
56923 T A chr13:48934223 T/A probably damaging 
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153353 G C chr13:49030485 G/C benign 
153353 G T chr13:49030485 G/T benign 
Potential Missense variants near position chr13:49033844 (at codon 661) 
gDNA 
position 
Reference 
allele 
Alternate 
allele 
Polyphen2 format Polyphen2 prediction 
156710 C A chr13:49033841 C/A benign 
156711 C A chr13:49033842 C/A probably damaging 
156714 G T chr13:49033845 G/T probably damaging 
156716 C A chr13:49033847 C/A probably damaging 
156717 T G chr13:49033848 T/G probably damaging 
 
Table 4.7 Enrichment of missense mutation within exon 20. Comparison between observed 
mutations and the simulated frequency of missense changes at amino acids and codons in exon 
20, to find localized pathogenicity within missense mutations. Only the significant results are 
reported here. 
Change 
(Codon or 
Amino 
Acid) 
99% CI of 
simulation 
Observed 
variants 
P 
value
CGG-TGG [0, 4] 6 0 
Arginine - 
Tryptophan 
[0, 4] 6 0 
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Table 5.1 Predicted and observed mutations in different substitution classes. Comparison 
between predicted and observed mutations on a separate dataset of de novo germline mutations. 
The 95% CI of predicted mutations is reported here. 
Substitution Class 95% CI of predicted 
mutations 
Observed mutations 
A-to-C [291, 363] 341 
A-to-G [1199, 1339] 1279 
A-to-T [295, 366] 316 
C-to-A [427, 511] 430 
C-to-G [350, 430] 430 
C-to-T [1862, 2036] 1952 
C-to-T at CpG only [726, 834] 816 
 
Table 5.2 Log likelihood of different sequence context models on a mutational data. The log 
likelihood of different de novo sequence context mutation models on a separate dataset of de 
novo germline mutations. 
Sequence model Log Likelihood 
heptanucleotide -29447 
trinucleotide -29718 
1mer+CpG -29714 
1mer -31196 
 
Table 5.3 Log likelihood of different sequence context models on coding variant data. The log 
likelihood of different de novo coding sequence context mutation models on a separate dataset of 
low frequency variants from EVS dataset. 
100 
 
Sequence model Log Likelihood 
heptanucleotide -3332725 
trinucleotide -3364132 
1mer+CpG -3509111 
1mer -3611400 
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FIGURES 
Figure 2.1 Intuition behind the substitution probability model. (a) Defining the non-Bayesian 
probability and Bayesian posterior probability of nucleotide substitution for a 7-mer context. Here I 
use the example CTACGAT, where position 4 is the polymorphic site and the three nucleotides 
located 5′ and 3′ constitute the remainder of that site’s local 7-mer sequence context. I count (i) 
the number of occurrences of that 7-mer context found in the reference genome and (ii) the 
number of times I observe a polymorphic substitution at position 4. The example shown here is a 
C-to-T substitution. To generate the posterior probabilities, I sum the observed counts of 
occurrences and substitutions with a count obtained from the modeled prior. I apply this 
mathematics to all 7-mer sequence contexts for all substitution classes and then merge the 
reverse-complementary pairs (the A-to-C class was merged with the T-to-G class, etc.). This 
results in a total of 24,576 parameters, each representing a unique 7-mer sequence context. (b) 
Illustration showing how the same 7-mer sequence context on different codon frames leads to 
different types of amino acid change. Depicted are three cases where a C-to-T substitution that 
occurs in the sequence context CTA[C/T]GAT at either position 1, 2 or 3 of a codon results in a 
synonymous, nonsynonymous or nonsense change in amino acid identity. 
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Figure 2.2 Substitution probabilities from 1KG and HapMap data. Scatter plot of nucleotide 
substitution probabilities inferred from 1000 genomes variants and separately from HapMap 
variants for each 7-mer sequence context change. The substitution probabilities in both cases are 
strongly correlated (R2 = 0.91, P << 10-100) with each other. 
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Figure 2.3 Substitution probabilities in different human populations. Genome-wide nucleotide 
substitution probabilities are correlated across different human populations. (a) The nucleotide 
substitution probabilities estimated from the 1-mer model for three human population groups 
(African, European, and Asian) obtained from the 1KG Project.  (b) The nucleotide substitution 
probabilities estimated from the 7-mer context in the same three populations. Because the x-axis 
for this plot represents 24,576 sequence contexts, it was not practical to list them individually as 
was done in part A, above. The contexts are represented graphically, sorted from lowest-to-
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highest nucleotide substitution probability, as observed in the African group. Data for the 
European and Asian groups was then represented according to the order obtained for the African 
group, to make comparison possible across the populations for any given sequence context. 
 
Figure 2.4 Variability in heptanucleotide substitution probabilities at CpG context. Simulations 
based on a fixed C-to-T substitution rate (blue) at CpG contexts do not capture the observed 
distribution of substitution probabilities (red) within the 7-mer sequence context. Rates predicted 
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from my regression model (black) closely match the substitution probabilities observed under the 
7-mer sequence context (R2 = 0.93). 
 
Figure 2.5 3-mer model and variability in heptanucleotide substitution probabilities at CpG 
context. Observed distribution of C-to-T substitution probabilities within a 7-mer CpG sequence 
context, compared to simulations assuming a 3-mer model. The distribution of substitution 
probabilities in a 7-mer context around a CpG site is significantly greater (P << 10-10) than 
expected, relative to the distribution of probabilities simulated assuming a 3-mer model. 
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Figure 2.6 C-to-T substitution probabilities and methylation patterns. Probabilities of C-to-T 
substitutions for the following sequence contexts: “CpG Me-” = CpG 7-mer contexts that were 
unmethylated in all sperm samples[110]; “CpG Me+” = CpG 7-mer contexts that were methylated 
in all sperm samples. *** represents P << 10-100. 
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Figure 2.7 Methylation intensity and heptanucleotide substitution probabilities at CpG context. 
Correlation between average methylation intensity versus probability of C-to-T substitution in CpG 
7-mer context. 
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Figure 2.8 Methylation (more tissues) and substitution probabilities at CpG context. Correlation 
between average methylation intensity versus probability of C-to-T substitution in CpG 7-mer 
context. (a) Scatter plot of average methylation intensity in brain samples against substitution 
probability at each 7-mer CpG context. (b) Scatter plot of average methylation intensity in oocyte 
samples against substitution probability at each 7-mer CpG context. (c) Scatter plot of average 
methylation intensity in blood samples against substitution probability at each 7-mer CpG context. 
(d) Scatter plot of average methylation intensity in blastocyst samples against substitution 
probability at each 7-mer CpG context. In all cases the substitution probability is moderately 
correlated (R2 ~ 0.3) with methylation intensity at each 7-mer CpG sequence context. 
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Figure 2.9 Substitution probabilities in intergenic noncoding region. Posterior probabilities of all 
classes of nucleotide substitution in the intergenic non-coding genome, estimated using the 7-mer 
context model. Sequences contexts are further stratified by color to indicate either the presence 
of a CpG (C at the polymorphic 4th position and G at the 5th position, for C-to-A, C-to-G and C-
to-T substitution classes = CpG+; else CpG-) or the ApT state (A at the polymorphic 4th position 
and T at the 5th position, for A-to-G and A-to-T substitution classes = ApT+; else ApT-). For A-to-
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C, the ApT state did not significantly contribute to variability in the estimated probability 
distribution. 
 
Figure 2.10 Distance from nearest gene and CpG sites. Box-and-Whisker plot of the distances 
between sequence contexts that contains a CpG site (C at polymorphic 4th position, fixed G at 
5th position) and the gene nearest to that context found in the human reference genome. “LOW” 
plots the distances from sequences contexts identified in the bottom 1% smallest substitution 
probabilities in the C-to-T substitution class (n=10). “ALL” represents the distances from all 
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sequences contexts containing a CpG (n=1024). “HIGH” represents the distances from 
sequences contexts in the top 1% smallest substitution probabilities from C-to-T substitution class 
(n=10).  Each distribution is significantly different from one other (pair-wise each are P << 10-100 
by Wilcoxon Rank-Sum Test). 
 
Figure 2.11 Methylation intensity at CpG sites. Box-and-Whisker plot of methylation intensity 
values in various sequence contexts containing a CpG site. Methylation intensity represents the 
average intensity values across all sperm samples[110]. “Poly-CpG” represents sequence 
contexts which segregate additional CpG dinucleotides beyond the CpG site at position 4 and 5 
(note that a 7-mer sequence context with a CpG site can segregate up to 2 additional CpG 
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dinucleotides). Each distribution is significantly different from one other (pairwise each are P < 10-
5 by Wilcoxon Rank-Sum Test). 
 
Figure 2.12 Substitution probabilities and recombination rate. Scatter plot of nucleotide 
substitution probabilities inferred from only 1000 genomes high recombination (rate > 3 cM/Mb in 
YRI population) and separately for low recombination (rate < 0.05 cM/Mb in YRI population) 
regions for each 7-mer sequence context change. The substitution probabilities in both cases are 
strongly correlated (R2 = 0.97, P << 10-100) with each other. 
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Figure 2.13 Substitution probabilities and human primate divergence. Human substitution 
probabilities are strongly correlated with Human-Chimpanzee and Human-Macaque divergence 
rates. (a) Scatter plot of nucleotide substitution probabilities against nucleotide divergence rates 
between human-chimpanzee at each 7-mer sequence context. (b) Scatter plot of nucleotide 
substitution probabilities against nucleotide divergence rates between human-macaque at each 
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7-mer sequence context. In both cases the substitution probabilities and divergence rates are 
strongly correlated (R2 = 0.96, P << 10-100) with each other. 
 
Figure 2.14 Substitution probabilities across variant frequency spectrum. Scatter plot of 
nucleotide substitution probabilities inferred from only 1000 genomes low frequency (1% and 
above MAF) and separately from rare (singletons and doubletons only) variants for each 7-mer 
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sequence context change. The substitution probabilities in both cases are strongly correlated (R2 
= 0.98, P << 10-100) with each other. 
 
Figure 3.1 Substitution probabilities in the coding region. Posterior probabilities of nucleotide 
substitution for each type of amino acid substitution in the coding genome, estimated using the 7-
mer coding context model. Sequences contexts are further stratified by color to indicate either the 
presence of a CpG (C at the polymorphic 4th position and G at the 5th position, for C-to-A, C-to-G 
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and C-to-T substitution classes = CpG +; else CpG -), and where evidence of substitution was 
only observed in the intergenic region. The presented inset zooms in specifically on the 
distribution for nonsense substitutions.  
 
Figure 3.2 Variability in coding substitution probabilities. Violin plot for trends in amino acid 
replacement types across different amino acids. In (a), note the mean probability is different 
between Glycine and Tyrosine substitutions, though the expected trend holds (synonymous > 
missense > nonsense). In (b), some amino acids substitutions deviate from this expected trend, 
owing to the CpG context in the coding genome. 
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Figure 3.3 Prioritizing pathogenic variants using heptanucleotide substitution probabilities. log10 
ratios of substitution probabilities from the 7-mer sequence context model using coding 
sequences matched to the intergenic non-coding sequences, for each type of substitution for all 
variants in the 1KG project or Human Gene Mutation Database (HGMD). Larger values indicate 
fewer substitutions in the coding genome than expected from matched non-coding sequences, 
consistent with the action of selective constraint. *** represents P << 10-100 and ** represents P < 
10-29. 
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Figure 3.4 Prioritizing pathogenic variants using trinucleotide substitution probabilities. log10 
ratios of substitution probabilities for the 3-mer model with codon context for coding sequences 
matched to non-coding sequences for each type of amino acid replacement. I consider all 
variants from the 1KG project (African, yellow) or the Human Gene Mutation Database (HGMD, 
orange). Larger values indicate fewer substitutions in the coding genome than expected from 
matched non-coding sequences (intolerance), consistent with selective constraint acting on these 
replacements. ** indicates P < 10-53 and NS indicates not significant by Wilcoxon Rank-Sum Test. 
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Figure 3.5 Gene scores from 1KG and EVS datasets. Gene scores based on the 7-mer coding 
context model calculated in 1KG (European) or EVS (European) datasets. 
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Figure 3.6 Gene scores across different gene sets. Box and whisker plot of gene scores from the 
model, stratified into statistically significant gene classes. Positive gene scores indicate 
intolerance to substitutions that change an amino acid. 
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Figure 3.7 Comparison of various gene score measures. Comparison of my presented gene 
score (Aggarwala) built from the 1KG African group using the coding 7-mer model to scores 
presented by (a)(Petrovski et. al.) or (b)(Samocha et. al.). Note that in (A) all HGNC genes ids 
could not be mapped to Ensembl 75 genes and in (B), only a subset of gene scores was publicly 
available. 
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Figure 3.8 Gene scores and Autism de novo mutations. Forest plot of Odds Ratio (OR) and the 
95% confidence interval (CI), and P-value when comparing the de novo mutational burden in 
cases versus controls, on intolerant genes (including or excluding known Autism genes) using 
different gene scoring methods. Aggarwala indicates gene score from this report, while Samocha 
and Petrovski refers to the intolerant gene list from those works respectively. 
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Figure 3.9 Amino acid scores and Autism de novo mutations. Forest plots of the mean amino 
acid score (95% CI) found from de novo mutations from various gene collections. Average score 
was based on variants ascertained in cases, except where noted (i.e., the first row: All genes in 
Controls). W/o: without. AC: indicates allele count for missense or nonsense changes only. * 
represents P < 0.01. 
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Figure 4.1 Algorithm to quantify unusual patterns of de novo mutations within a class. My 
approach involves three steps. First, I identify the genomic target (base pair territory) in which 
mutations will be characterized, and the total number of mutations found in that territory. I then 
distribute this total number of mutations over the target territory using a background model of 
mutation rate. Second, I find the expected number of mutations in different categories (Exon, 
mutational type like Nonsense or specific Amino Acid) using the previous distribution samples. 
Third and finally, I compare this to the observed number of mutation to detect statistical 
enrichment in a category beyond expectation. In this toy example depicted here, I focus on the 
genomic territory that can generate nonsense mutation (shown in red), and imagine that I have 
identified 10 de novo mutations that are nonsense. First, I identify eligible base pairs and that can 
result in a nonsense change. Next, I calculate the probability of mutation at each eligible base 
pair as the sum of substitution probabilities of that sequence context changing to a stop codon 
(shown in red). Second, I then distribute the mutations over multiple simulations from a 
multinomial distribution, and find the distribution of the expected number of mutations at each of 
these eligible base pairs. I am particularly interested in cases where the observed number of 
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mutations at a subclass (exon or an amino acid) is greater than what I see in simulations, as this 
is compatible with disease-relevant pathogenicity for this class of mutation, or position where the 
mutation(s) is located. Third and finally, for a particular subclass I combine the expected 
mutations at different eligible base pairs and compare the overall expected distribution with 
observed, and conclude enrichment. 
 
Figure 4.2 Detecting enrichment of nonsense mutations. Comparison of the overall observed 
number of mutations to the simulated frequency of nonsense mutations in both RB and ExAC 
datasets. 
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Figure 4.3 Detecting enrichment within nonsense mutations. Comparison of the observed 
number of mutations to the simulated frequency of nonsense mutations in RB, across exons 2 to 
27. The asterisk (*) denotes that the observed number falls outside the 99% confidence interval 
(i.e., P < 0.01). CI: Confidence Interval. 
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Figure 4.4 Detecting enrichment of splice mutations. Comparison of the overall observed number 
of mutations to the simulated frequency of essential splice and intronic mutations in both RB and 
ExAC datasets. 
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Figure 4.5 Detecting enrichment within essential splice acceptor mutations. Comparison of 
observed mutations and the simulated frequency of essential splice acceptor mutations in RB 
(99% CI) to find exon specific differential pathogenicity within essential splice mutations. Exons 
where the observed mutations are higher or lower than the 99% confidence interval of simulations 
are denoted by an asterisk (*). 
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Figure 4.6 Detecting enrichment within essential splice donor mutations. Comparison of the 
observed number of mutations to the simulated frequency of essential splice donor mutations in 
RB, across exons 2 to 27. The asterisk (*) denotes that the observed number falls outside the 
99% confidence interval (i.e., P < 0.01). CI: Confidence Interval.  
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Figure 4.7 Splice mutations and their effect on codon structure. Donor splice mutations in Exons 
5, 6 and 12, and their effect on codon structure. The codon structures are shown prior and after 
the donor splice mutation. The donor splice mutation results in exon skipping or deletion, but can 
also cause a frameshift mutation in certain cases. 
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Figure 4.8 Detecting enrichment of missense mutations. Comparison of the overall observed 
number of mutations to the simulated frequency of missense mutations in both RB and ExAC 
datasets. 
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Figure 4.9 Detecting enrichment within missense mutations. Comparison of the observed number 
of mutations to the simulated frequency of missense mutations in RB, across exons 2 to 27.  
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Figure 4.10 Detecting enrichment within missense mutations in the pocket domain. Comparison 
of the observed number of mutation to the simulated frequency of missense mutations over 
codons in the pocket domain of RB1. Here, a sliding window of 10 amino acids on either side of 
the codon was considered. Dotted line denotes the gap in the pocket domain.  
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Figure 4.11 Relative rates of mutations across different categories. Comparison of the relative 
rates of different types of de novo mutations, normalized to the rate of nonsense mutations. 
Plotted is the mean of the ratio of observed number of mutations over expected based on the 
computational model. Mutational categories that have a different rate from the nonsense category 
(P < 0.01) are denoted by an asterisk (*). CI: Confidence Interval.  
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Figure 5.1 Correlation between de novo mutation rate estimates. Scatter plot of de novo mutation 
rate estimates at each heptanucleotide sequence context from polymorphism data from 
individuals of African and European ancestry. 
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Figure 5.2 Predicted vs observed mutations at a CpG mutation motif. Boxplot of predicted de 
novo mutations, in a separate sample of germline mutations from whole genome sequencing of 
78 trios at TACG motif changing to TATG. Predicted mutations are shown for heptanucleotide 
and trinucleotide sequence context based mutation rate estimates. Shown in dotted green line is 
the actual observed mutations at the original TACG motif changing to TATG. 
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Figure 5.3 Predicted vs observed mutations at an ApT mutation motif. Boxplot of predicted de 
novo mutations, in a separate sample of germline mutations from whole genome sequencing of 
78 trios at [C/T]CAAT motif changing to [C/T]CAGT. Predicted mutations are shown for 
heptanucleotide and trinucleotide sequence context based mutation rate estimates. Shown in 
dotted green line is the actual observed mutations at the original [C/T]CAAT motif changing to 
[C/T]CAGT. 
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Figure 5.5 Variability in mutation rate between genes. Boxplot of predicted de novo mutation rate 
at each defined coding transcript using heptanucleotide sequence context based mutation rate 
estimates. 
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Figure 5.6 Variability in mutation rate between genes due to sequence context. Boxplot of 
predicted de novo mutation rate at each defined coding transcript using heptanucleotide 
sequence context based mutation rate estimates, further normalized by gene length. Shown in 
green is the average per base pair overall mutation rate in the coding region. 
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Figure 5.7 Variability in mutation rate across exons. Boxplot of predicted de novo mutation rate 
across the exon in each defined coding transcript using heptanucleotide sequence context based 
mutation rate estimates, further normalized by gene length. Shown in green is the average per 
base pair overall mutation rate in the coding region. 
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SUPPLEMENTARY FILES 
Supplementary File 2.1 Robustness of substitution probabilities. Pearson’s correlation and Root 
Mean-Squared Error (RMSE) for substitution probabilities estimated from the training (all but the 
two listed chromosomes) and testing (the two listed chromosomes) sets from the intergenic non-
coding genome. I present measurement for null (i.e., fixed rate), 1-mer, 3-mer, 5-mer and 7-mer 
models. 
Supplementary File 2.2 LL comparison of different sequence context models. P-values for each 
likelihood ratio test comparing competing sequence context models (null, 1-mer, 3-mer, 5-mer 
and 7-mer), using all data from the intergenic non-coding genome. The matrix is symmetric, so “-” 
is presented where appropriate. 
Supplementary File 2.3 Comparison of different sequence models on HapMap data. P-values 
and Bayes factor comparing sequence context models (1-mer, 3-mer, 5-mer and 7-mer) using all 
HapMap variant data from the intergenic non-coding genome. 
Supplementary File 2.4 Bayes factor comparison of different sequence models. Natural 
logarithm of the approximate Bayes Factor comparing competing sequence context models (null, 
1-mer, 3-mer, 5-mer and 7-mer), using all data from the intergenic non-coding genome. The 
matrix is symmetric, so “-” is presented where appropriate. 
Supplementary File 2.5 Variability in substitution classes explained by different models. 
Stepwise regression model analysis for each substitution class on various models considered in 
the intergenic non-coding region. Data for the training phase was based on the collection even 
numbered chromosomes; data for the testing phase was based on odd numbered chromosomes. 
“# Features” denotes the features selected for that model. “AIC” is the Akaike Information 
Criterion, “MSE” represents Mean-squared Error; “adj-R2” is the adjusted R2 from the model. The 
best performing model (lowest MSE after 8-fold cross validation) are highlighted in red. 
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Supplementary File 2.6 Sequence features and their effect on substitution probabilities. 
Aggregated sequence context features and their effect on the substitution probabilities for all 
classes of substitutions in the intergenic non-coding region. Order denotes the number of 
interacting nucleotides in the context. “BETA” indicates the regression coefficient for the 
sequence context for the given substitution class (i.e., A-to-C, A-to-G, etc.). “All_DIRXN” denotes 
the direction of effect for the feature on the substitution probability (+ indicates increase higher 
substitution probability, – indicates lower substitution probability). I present estimated values 
using (I) all data from 1KG, (II) data used in the training phase (all even-numbered 
chromosomes), and (III) data used for the testing phase (all odd-numbered chromosomes). (a) 
Substitution classes for sequence contexts outside of CpG sites (b) Substitution classes for 
sequences context including CpG sites (polymorphic 4th position is C and 5th position fixed at G). 
Supplementary File 2.7 Nucleotide substitution probabilities in the noncoding region. Posterior 
probabilities of nucleotide substitution for all substitution classes within all 7-mer sequence 
contexts in the intergenic non-coding region for African, European and Asian populations groups 
(1KG project). The forward and reverse complementary sequences are presented for each 
probability. 
Supplementary File 2.8 Comparison of different models across frequency spectrum. P-values 
and Bayes factor comparing sequence context models (1-mer, 3-mer, 5-mer and 7-mer) using all 
data from the intergenic non-coding genome. (a) Sequence context rates inferred from low 
frequency (1% and above MAF) variants from the 1000 genomes project (b) Sequence context 
rates inferred from rare (singletons and doubletons) variants from the 1000 genomes project. 
Supplementary File 3.1 Nucleotide substitution probabilities in the coding region. Posterior 
probabilities of nucleotide substitution for all substitution classes within all 7-mer sequence 
contexts in coding region for African, European and Asian populations groups (1KG project). The 
forward and reverse complementary sequences are presented for each probability. The 
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corresponding amino acid changes associated with each substitution class within the 7-mer 
sequence context, as well as their reverse complements, are also listed in the table. 
Supplementary File 3.2 Estimates of the variability in AA substitution probabilities. (a) Simulated 
and observed variance in nucleotide substitution probabilities grouped by type of amino acid 
replacement class. (b) Simulated and observed variance in nucleotide substitution probabilities, 
stratified for each possible types of amino acid replacement. Reported simulated values are 
based on 1,000,000 repetitions, based on a fixed rate model for each class of substitution. 
Supplementary File 3.3 Gene Scores for functional intolerance. Gene scores and annotations 
for >16,000 transcripts in humans. I annotate each gene using Ensembl, attached to a specific 
transcript identifier. Columns 3 through 14 refer to the annotation attached to set membership 
(Essential, Ubiquitous, Immune, Olfactory, Keratin, Omim de novo, dominant, and 
haploinsufficient). Details and citations describing how each gene set was identified are 
presented in the Methods. The last three columns are gene scores calculated by my approach 
(for the African population), and various published methods. 
Supplementary File 3.4 Amino Acid scores for specific AA functional intolerance. Amino acid 
tolerance scores for >16,000 transcripts in humans. These scores quantify the number of excess 
substitutions for each type of amino acid change relative to expected, with larger scores 
indicating fewer substitutions (intolerance) for that specific amino acid. Scores were developed 
using 1KG project data using the African group. 
Supplementary File 4.1 De novo variants in RB1 gene from RB patients. All de novo germline 
variants in RB1 gene of patients with RB. “gDNA position” is the nucleotide position in the 
GENBANK accession number L11910 of the gene.  
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Supplementary File 4.2 Singleton ExAC variants in RB1 gene. All ExAC variants in RB1 gene 
that were considered in my analysis. “gDNA position” is the nucleotide position in the GENBANK 
accession number L11910 of the gene.  
Supplementary File 4.3 De novo nonsense variants from an external dataset. All Nonsense 
variants in RB1 gene from Onadim and Houdayer groups. “gDNA position” is the nucleotide 
position in the GENBANK accession number L11910 of the gene.  
Supplementary File 5.1 heptanucleotide mutation rate estimates from AFR polymorphism data. 
De novo mutation rate estimate at each heptanucleotide sequence context (“alpha”) to another 
(“beta”) from polymorphism data of individuals from African ancestry.  
Supplementary File 5.2 heptanucleotide mutation rate estimates from EUR polymorphism data. 
De novo mutation rate estimate at each heptanucleotide sequence context (“alpha”) to another 
(“beta”) from polymorphism data of individuals from European ancestry. 
Supplementary File 5.3 trinucleotide de novo mutation rate estimates. De novo mutation rate 
estimates at each trinucleotide sequence context (“alpha”) to another (“beta”) from polymorphism 
data of individuals from African ancestry. 
Supplementary File 5.4 1mer+CpG de novo mutation rate estimates. De novo mutation rate 
estimate at each 2mer sequence context (“alpha”) to another (“beta”) from polymorphism data of 
individuals from African ancestry. The first position at each 2mer context is the base which is 
mutated. The rates reported here use the 1mer de novo mutation rate estimates for all changes, 
except for C-to-T mutation at CpG site. 
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